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Abstract  
Retinoblastoma Binding Protein 6 (RBBP6) is a RING finger-containing protein which plays a critical 
role in the 3’-end processing of mRNA transcripts.  It is a constituent of the human pre-mRNA 
processing complex but also interacts directly with core splicing-associated proteins. RBBP6 also 
interacts with both major tumour suppressor proteins p53 and pRb and is known to play a critical 
role in suppression of p53 during development, in cooperation with MDM2. Through its RING finger 
it interacts with the C-terminus of the oncogenic protein Y-Box Binding Protein 1 (YB-1) both in vitro 
and in vivo, catalysing its ubiquitination and degradation in the proteasome. YB-1 is closely 
associated with tumour progression, poor patient prognosis and chemotherapeutic resistance, 
making it a promising target for therapeutic intervention. Unpublished data from our laboratory 
suggests that RBBP6 is able to poly-ubiquitinate YB-1 in vitro, using UbcH1 as the ubiquitin-
conjugating enzyme (E2). 
This study aims to identify RBBP6 RING protein-protein interactions involved in the down regulation 
of YB-1 by RBBP6. These interactions include the C-terminal fragment of YB-1 (substrate), MDM2 
(E3) and UbcH1 (E2).  The C-terminal fragment of YB-1, denoted YB-1220-324, was successfully cloned 
and expressed in bacteria and demonstrated to interact directly with the RBBP6 RING finger domain 
in in vitro affinity pull down assays. This is in good agreement with our unpublished data that RBBP6 
is able to ubiquitinate full length YB-1 as well as the YB-1220-324 fragment.   
UbcH1 was successfully expressed and shown to interact directly with RBBP6 RING in in vitro affinity 
pull down assays. This is also in agreement with our data showing that RBBP6 is able to ubiquitinate 
YB-1 using UbcH1 as E2. 15N-labelled samples of RBBP6 RING was successfully expressed in bacteria 
and used to investigate the putative interaction with UbcH1 in NMR-based chemical shift 
perturbation assays. However no interaction was observed, possibly because the sample of UbcH1 
was subsequently found using mass spectrometery to be partially degraded.  
GST-tagged RBBP6 RING was able to precipitate MDM2 from HeLa lysate. This extends previous 
reports that full length RBBP6 and MDM2 interact directly and play a role in the suppression of p53 
during development.  The result was validated by showing that GST-MDM2 was able to precipitate 
RBBP6 RING in in vitro.   
This study includes a side project which involved the cloning and expression of DWNN-GG. GST-HA-
DWNN-GG was successfully cloned and expressed in bacteria. An HA tag was included immediately 
upstream of DWNN-GG for immunodetection using anti-HA antibodies; the construct was designed 
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in such as way that it could be re-used to generate HA-tagged versions of existing constructs cloned 
into pGEX-6P-2. 
The above findings lay the foundation for future structural and functional studies of the involvement 
of RBBP6 in regulation of the cancer-related proteins p53 and YB-1, which may have far-reaching 
consequences in the fight against cancer.       
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Chapter 1 
 
Literature review 
1.1. Introduction 
Retinoblastoma Binding Protein 6 (RBBP6), also known as p53 Associated Cellular Protein Testis-
derived (PACT) or Retinoblastoma Binding Q protein 1 (RBQ-1), is a RING finger-containing protein 
that forms part of the 3’-end polyadenylation complex in humans and plays a role in regulation of 3’-
end processing in yeast and humans (Lee and Moore. 2014; Di Giammartino et al., 2014).  It also acts 
as a negative regulator of p53 by activating the poly-ubiquitination activity of Murine Double Minute 
2 (MDM2) (Li et al., 2007). 
In 2008 Chibi and co-workers showed using a yeast 2-hybrid screen that the RING finger domain of 
RBBP6 interacts directly with the C-terminal domain of transcription factor Y-Box Binding Protein 1 
(YB-1)  and with the transcriptional repressor zBTB38 (Chibi et al., 2008). RBBP6 has subsequently 
been shown to catalyse the ubiquitination and degradation of both YB-1 and zBTB38 in vitro and in 
vivo.  Knockdown of RBBP6 leads to accumulation of zBTB38, leading to sensitivity to DNA damage 
(Miotto et al., 2014). The functional consequences of suppression of YB-1 by RBBP6 are still being 
established. 
YB-1 is a multifunctional, pro-cancerous transcription factor whose transcriptional activity is strongly 
correlated with aggressive tumourigenesis, metastasis and chemotherapeutic resistance as well as 
poor prognosis in a number of cancers, in particular breast cancer (Basaki et al., 2010). Over-
expression of YB-1 is associated with drug resistant tumours by promoting transcriptional activation 
of ATP-binding cassette transporter P-glycoprotein, which is encoded by the drug resistant gene 
Multi Drug Resistant gene 1 (MDR1)(Chattopadhyay et al., 2008).  
The yeast 2-hybrid screen utilised by Chibi and co-workers localised the interaction between RBBP6 
and YB-1 to the extreme C-terminus of YB-1, residues 262-324. Previous attempts to express the 
above region of YB-1 in bacteria failed, presumably because it was too small to form a structured 
protein. The first aim of this work was therefore to identify and express a larger region of the C-
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terminus of YB-1 suitable for in vitro interaction studies with the RING finger of RBBP6, with the 
eventual aim of carrying out NMR-based interaction studies. 
Fully in vitro ubiquitination studies carried out in our laboratory suggest that RBBP6 is able to 
catalyse poly-ubiquitination of YB-1 in conjunction with the ubiquitin-conjugating enzyme UbcH1 (A 
Faro and D.J.R. Pugh, manuscript in preparation). If this is true we would expect to find an 
interaction between RBBP6 and UbcH1 in vitro. A second aim of this work was therefore to over-
express both UbcH1 and the RING finger from RBBP6 in bacteria and test their interaction using 
immunoprecipitation and NMR-based interaction studies.  
The work of Li and co-workers cited above suggests that RBBP6 cooperates with MDM2 in poly-
ubiquitinating p53, leading them to propose that RBBP6 acts as a molecular scaffold, bringing MDM2 
and p53 together on the p53-binding domain identified in the C-terminus of RBBP6 (Simons et al., 
1997, Li et al., 2007). An alternative explanation, suggested by our own unpublished data, is that 
RBBP6 and MDM2 interact through their respective RING finger domains, in a manner similar to that 
by which MDM2 and MDMX interact (Wang at el., 2011). In order to test this hypothesis, a third aim 
of the thesis was to express the RING finger domains of both proteins in bacteria and investigate 
their interaction in vitro using immunoprecipitation and NMR. 
The investigations described in the following chapters are aimed at furthering our understanding of 
the role played by RBBP6 in regulating proteins involved in cancer, including p53, MDM2, YB-1 and 
UbcH1, primarily by understanding the interactions between them. The hope is that by 
understanding more about these interactions we may be able to design ways of modulating them 
that may, eventually, lead to the development of novel anti-cancer therapies. At the very least it 
would enable us to design non-interacting mutants of the proteins that can serve as negative 
controls in functional assays. 
1.2. Retinoblastoma Binding Protein 6 (RBBP6) 
1.2.1. Structure of RBBP6 
Orthologues of human RBBP6 are found in all eukaryotic, but not in prokaryotic, genomes, in many 
cases at single copy number. Analysis of the amino acid sequences reveals the presence of domains 
previously identified in other proteins, as shown in Figure 1. All eukaryotes express an isoform 
containing the DWNN domain, a zinc knuckle and a RING finger domain, reading from the N-
terminus. Zinc knuckles are found in many other proteins, in many of which they play a role in 
nucleic acid binding (Krishna et al., 2003). RING fingers are found in many E3 ubiquitin ligases, where 
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their function is to bind to the ubiquitin-conjugated E2, promoting transfer of ubiquitin to the 
substrate. The DWNN domain is found only in members of the RBBP6 protein family, always at the 
N-terminus, and has a structure similar to that of ubiquitin (Pugh et al., 2006). Lower eukaryotes 
such as fungi and plants contain only these three domains whereas higher eukaryotes contain 
additional domains, including regions resembling an SR domain, a proline-rich domain and regions 
reported to promote interaction with p53, pRb and nuclear localisation (Pugh et al., 2006; Simons et 
al., 1997; Witte and Scott 1997).  
The single human RBBP6 gene gives rise to a number of different transcripts (and thereby protein 
isoforms) through a combination of alternative splicing and alternative promoters (Pugh et al., 2006; 
Pretorius et al., 2013). Isoform 1 consists of the full length protein of 1792 amino acid residues; 
Isoforms 2 and 4 represent alternatively-spliced fragments of 1752 and 952 residues respectively 
(Pugh et al., 2006). Isoform 3 is a 13 kDa protein that is expressed from an alternative promoter; of 
its 118 residues the first 100 are the same as isoform 1 and contain primarily the DWNN domain. The 
last 18 residues of isoform 3 are unique to this isoform. The function of isoform 3 remains unclear 
but in 2011 Mbita and co-workers reported it is regulated independently of isoform 1 and is 
deregulated in various cancers, possibly playing a role in cell cycle regulation (Mbita et al., 2011). Di 
Giammartino and co-workers have since reported that isoform 3 regulates mRNA splicing by 
competing with the DWNN domain on full length RBBP6 (Di Giammartino et al., 2014). 
 
Figure 1: The domain structure of the RBBP6 family. All eukaryotic genomes contain a minimal isoform containing the 
DWNN, zinc knuckle and the RING finger domains. In this thesis the fragment of human RBBP6 consisting of these three 
domains is referred to as R3. Higher eukaryotes include C-terminal extensions as well as an independently-expressed 
fragment consisting almost exclusively of the DWNN domain. RBBP6 has not been found in prokaryotes, which may be 
attributed to the role of RBBP6 in RNA processing. Figure adapted from Pugh et al,. (2006). 
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1.2.2. Role of RBBP6 in mRNA processing 
The Saccharomyces cerevisiae orthologue of human RBBP6, which is known as Mutant PCFII 
Extrogenic suppressor 1 (Mpe1), is a 440 residue protein containing the DWNN domain, the zinc 
knuckle and the RING finger domain (Vo et al., 2001).  Vo and colleagues identified Mpe1 to be an 
integral component of the Cleavage and Polyadenylation Factor (CPF). They demonstrated that 
Mpe1 is essential for mRNA processing by inactivating it with an antibody specific to the protein 
which resulted in defective 3’-end mRNA processing in yeast. They concluded that Mpe1 is essential 
for specific cleavage and polyadenylation of pre-mRNA, by promoting the complexing of Cleavage 
Factor One (CF1) complex with the CPF. Later Shi and co-workers showed that RBBP6 is a member of 
the human 3′-end processing complex by isolating and purifying a functional human pre-mRNA 
processing complex which they then subjected to mass spectrometry to identify the component 
proteins (Shi et al., 2009). More recently Lee and Moore have directly confirmed Mpe1 role in 
complexing CF1 with CPF, and shown that the DWNN domain is essential for this function (Lee and 
Moore 2014). These findings are in good agreement with the demonstration by Di Giammartino and 
co-workers using nuclear extracts of human cells that knockdown of RBBP6 abolished 3’-end 
cleavage but not poly-adenylation (Di Giammartina et al., 2014). 3’-end cleavage was restored 
following addition of a recombinant fragment of RBBP6 comprising the DWNN - zinc knuckle - RING 
finger, which in this thesis is referred to as R3. They concluded that RBBP6 is a regulator of 3’-end 
processing. 
Consistent with a role in mRNA processing, human RBBP6 contains a serine/arginine (SR) rich region 
similar to those found in many pre-mRNA splicing factors (Witte et al., 1997). Furthermore RBBP6 
has been reported to localize to nuclear speckles, to which elements of the splicing machinery are 
known to localize (Mbita et al., 2012). Witte and Scott showed that a truncated form of RBBP6, 
which they named Proliferation Potential-Related protein (P2P-R), associates closely with 
heterogeneous nuclear ribonucleoproteins (hnRNPs), which are involved in RNA processing, and can 
be purified using a protocol specific for hnRNPs (Witte and Scott, 1997). They also showed that P2P-
R co-precipitates with SmB, one of the core splicing proteins. Another of the core splicing proteins, 
SmG, was shown by Chibi and co-workers to interact with the N-terminal DWNN domain of human 
RBBP6 in a yeast 2-hybrid screen (Chibi et al., 2008). 
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1.2.3. Role of RBBP6 as an ubiquitin-ligase (E3)  
In addition to its role in mRNA processing, RBBP6 is known to play a role in ubiquitination through its 
RING finger domain. As described above, RING fingers are found in many E3 ubiquitin-ligase enzymes 
where their function is to recruit the ubiquitin-conjugated E2 so that the ubiquitin can be transferred 
to the substrate, which is recruit by the substrate-binding domain also forming part of the E3 (Kim et 
al., 2007). 
The structure of the RING finger domain from human RBBP6 was solved by Nuclear Magnetic 
Resonance Spectroscopy (NMR) in 2011 and found to coordinate 2 zinc ions by 8 cysteine residues in 
a C4C4 configuration (Kappo et al., 2011). The topology is identical to that of the C3HC4 RING 
illustrated schematically in Figure 2, although in RBBP6 the histidine is replaced by a cysteine. Similar 
to many other RING finger domains, the RBBP6 RING was found to form a homodimer in solution 
and the dimerization interface was found to be identical to that found in the MDM2 homodimer and 
the BARD/BRCA1 and MDM2/MDMX heterodimers (Brzovic et al., 2002 and Linke et al., 2008). In 
many cases dimerization has been shown to be essential for E3 ligase activity (Plechanovova et al., 
2012). 
 
 
Figure 2: The Zn ion coordination of the RING finger domain. The metal-ligand pairs 1 and 3 coordinate one zinc ion, while 
pairs 2 and 4 coordinate the second one in a ‘cross-brace’ arrangement. This schematic illustrates a C3HC4 RING; in RBBP6 
the histidine ligand is replaced by cysteine, making it a C4C4 RING. Figure taken from Kosarev et al 2002. 
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Using RBBP6-knockout mice, Li and co-workers showed that RBBP6 acts as a suppressor of the 
tumour suppressor p53 during development. The tumour suppressors p53 and pRb play essential 
roles in regulating cell cycle progression and apoptosis, in response to different stresses like DNA 
damage and abnormal proliferative signals (Weinberg 2006). These proteins must be tightly 
controlled for normal cell growth and the prevention of tumour development (Weinberg 2006). This 
is the function of MDM2, which mediates the ubiquitination of p53 and its degradation in the 26S 
proteasome (Yang et al., 2004). Li and co-workers showed that knockout of RBBP6 leads to over-
expression of p53 and widespread ectopic apoptosis, resulting in lethality by embryonic day 7.5. In a 
p53 negative background the embryos survived longer (until day 11.5), indicating the presence of an 
interaction between p53 and RBBP6 at the genetic level. They went on to demonstrate that at the 
protein level RBBP6 interacts directly with MDM2. They concluded from this that RBBP6 is required 
for poly-ubiquitination of p53 by MDM2, making it an essential part of the MDM2/p53 regulatory 
system. Their results suggest that suppression of p53 by RBBP6 is definitely important during 
development, when p53 levels need to be kept low to avoid inappropriate apoptosis and when the 
role of p53 in tumour suppression is likely to be less important than in the mature organism. These 
finding are consistent with those of Mather and colleagues who earlier concluded that RBBP6 is 
essential for embryonic development in Drosophila melanogaster (Mather et al., 2005). 
The work of Li and co-workers suggests that RBBP6 facilitates ubiquitination of p53, but does not 
itself take part in ubiquitination. They proposed that RBBP6 may play the role of a scaffolding 
protein, involving the binding of p53 to a previously-identified site on the C-terminus of RBBP6, 
thereby bringing MDM2 into close proximity with p53 (Simons et al., 1997). However it is also 
possible that RBBP6 plays a role similar to that played by MDMX, which activates the poly-
ubiquitination activity of MDM2 by forming a heterodimer with MDM2 through their respective 
RING finger domains (Wang et al., 2011). 
In addition to p53, other proteins have been identified as possible substrates for ubiquitination by 
RBBP6. These include Y-Box Binding Protein 1 (YB-1), which is described in detail below, and the 
transcriptional repressor zBTB38. An interaction between RBBP6 and zBTB38 was first identified by 
Chibi and co-workers (Chibi et al., 2008) using a yeast 2-hybrid screen and subsequently Miotto and 
co-workers reported that RBBP6 catalyses ubiquitination and degradation of zBTB38, leading to up-
regulation of the replication factor MCM10 (Miotto et al., 2014). They concluded that RBBP6 is a 
causal factor in cancer by stabilizing the replication factor MCM10 which promotes genomic 
stability.  
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1.2.4. Role of RBBP6 in tumourigenesis  
Due to the extensive involvement of YB-1 in a host of different cancers, regulation of YB-1 by RBBP6 
implicates RBBP6 in regulation many of these cancers. Consistent with this, there is direct evidence 
for the involvement of RBBP6 in a number of cancers.  
Oesophageal cancer 
Yoshitake and co-workers reported that RBBP6 is over-expressed in oesophageal cancer cells but not 
in normal oesophageal epithelial cells (Yoshitake et al., 2004). They went on to generate antibodies 
against RBBP6 with which they were able to decrease the size of tumours. They concluded that 
RBBP6 may be an ideal target for immunotherapy for patients with oesophageal cancer.  
Lung cancer 
Knockdown of RBBP6 with siRNA in lung cancer cells resulted in an increase in Bax/Bcl2 mRNA which 
suggests that RBBP6 has an anti-apoptotic effect in lung cancer cells (Motadi et al., 2010). This may 
be due to RBBP6 having a negative effect on p53 which results in enhanced cell proliferation and 
inhibition of apoptosis.  
Colon cancer 
Chen and co-workers reported in 2013 that over-expression of RBBP6 is predictive of poor prognosis 
in colon cancer. They also reported that when RBBP6 over-expression is combined with mutant p53 
patient prognosis worsens dramatically over a short period (Chen et al., 2013). 
Gastric cancer 
Morisaki and co-workers showed using mass spectrometry and RT-PCR that RBBP6 is up-regulated in 
gastric cancer cells but not in normal cells. They identified RBBP6 as a promising biomarker and 
therapeutic target for gastric cancer (Marisaki et al., 2014). 
1.2.5. Unpublished data relating to the ubiquitination activity of RBBP6 
Using fully in vitro ubiquitination assays, members of our laboratory have shown that the R3 
fragment of human RBBP6 (residues 1-335) is able to poly-ubiquitinate p53 with the assistance of 
MDM2, leading to degradation of p53 in the proteasome (LS Jooste, A. Faro and D.J.R. Pugh, 
manuscript in preparation). Acting independently R3 and MDM2 were able to mono- or multiply 
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mono-ubiquitinate p53, but degradation in the proteasome only happened in the presence of both 
R3 and MDM2.  This is consistent with the findings of Wang and colleagues (Wang et al., 2011) that 
MDM2 is unable to poly-ubiquitinate on its own, but must be activated by MDMX. It is also 
consistent with the findings of Li and co-workers (Li et al., 2007) that RBBP6 is unable to catalyse 
degradation of p53 in vivo. However our finding that R3 is able to mono-ubiquitinate p53 is novel. 
Furthermore, the fact that R3 is able to activate the poly-ubiquitination activity of p53 in vitro calls 
into question the scaffold model of RBBP6 activity, because R3 is a far smaller protein than RBBP6 
and does not contain the reported p53-binding domain located near the C-terminus of RBBP6.  
Results from our laboratory have also shown that the R3 fragment of RBBP6 is able catalyse poly-
ubiquitination of Y-Box Binding Protein-1 (YB-1), with the assistance of the ubiquitin-conjugating 
enzyme UbcH1 (A. Faro and D.J.R. Pugh, manuscript in preparation). The importance of YB-1 is 
discussed in more depth in the following section.   
1.3. Y-Box Binding Protein 1 (YB-1)     
YB-1 is a DNA and RNA binding protein that is involved in a number of processes including mRNA 
packaging, regulation of mRNA stability, pre-mRNA transcription and splicing, translation and DNA 
repair (Dmitry et al., 2013). It belongs to the Y-Box Binding family of proteins and was first 
discovered for its ability to bind the inverted Y-box motif (CCAAT) in the promoter of major 
histocompatibility complex class II genes (Didier et al., 1988). Y-Box Binding proteins are divided into 
3 subfamilies: the first subfamily, YB-1, is specific to somatic cells, and includes human YB-1, Chicken 
CHK-YB-1, rabbit p50, mouse MSY-1, bovine EFI-A and FRGY from Xenopus leavis. The second 
subfamily, YB-2, is specific to germ cells and includes mouse MYS-2 and the human proteins dbpC 
and contrin. The third subfamily, YB-3, contains proteins that are synthesized only during embryonic 
development. Two isoforms of YB-3 mRNA, a short and a long one, are produced by alternative 
spicing of pre-mRNA. Proteins in this subfamily include dbpA protein, mouse MSY-3, and YB-3 from 
X. leavis (Eliseeva et al., 2011). 
1.3.1. Structure of YB-1 
Despite migrating on SDS-PAGE at an apparent molecular weight of 50 kDa, which accounts for the 
alternative name p50, YB-1 has a molecular weight of only 36 kDa. It is made up of three domains: 
an N-terminal alanine/proline rich domain (A/P domain), which has no regular secondary structure 
and appears to be intrinsically disordered (Dmitry et al., 2013); a cold shock domain (CSD), which has 
a five stranded β-barrel structure similar to that of bacterial CSD and consensus sequences RNP-1 
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(K/N-G-F/Y-G-F-I/V) and RNP-2 (V-F-V-H-F) that mediate interaction with nucleic acids (Kloks et al., 
2002); and a C-terminal domain (CTD) which contains alternating clusters of positively and negatively 
charged amino acids (Fig 3 A) (Dmitry et al., 2013). This domain also appears to be intrinsically 
disordered with an irregular secondary structure. The state of folding of these three domains is 
clearly illustrated by the PONDR VL_XT server (www.pondr.com), which predicts the A/P domain and 
the CTD to be unfolded (Fig 3 B) (Eliseeva et al., 2011). 
 
 
Figure 3: The domain organization of YB-1. (A) YB-1 is a 324 amino acid residue protein composed of three domains: the 
disordered A/P domain (residues 1-50), the β-barrel shaped CSD (residues 51-128) and the disordered CTD with clusters of 
positively and negatively charged amino acids (residues 129-324). Figure taken from Dmitry et al.(2013). (B) The A/P 
domain and CTD of YB-1 appear to be disordered based on the PONDR VL_XT (www.pondr.com) algorithm. Values ≥0.5 
correspond to disorder. On the other hand the CSD appears well folded. Figure taken from Eliseeva et al.(2011).  
 
 
It is also well known that many disordered proteins only adopt a fixed tertiary structure upon 
binding to a specific ligand, as is the case with p53 (Uversky and Dunker. 2010). Thus the structure of 
YB-1 may vary depending on the type of ligand (DNA, RNA or its numerous protein binding partners) 
and region of interaction. YB-1 has the ability to form homo-multimeric complexes up to 800 or 1000 
kDa (Evdokimova et al., 1995); this may be due to the formation of salt-bridges between positively 
charged arginines and negatively charges aspartic and glutamic acids, which are abundant in the 
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CTD. Another contributor to the oligemeric properties of YB-1 is the formation of hydrogen bonds 
between the guanidine groups of arginine and aromatic groups of phenylalanine and tyrosine which 
are also abundant in YB-1.   
All three domains of YB-1 are involved in protein-protein interactions as well as nucleic acid binding 
(Fig 4). The A/P domain contains binding sites for p53, cyclin D1 and the splicing factor SRp30c. The 
CSD contains binding sites for Akt kinase and FBX33 (Sutherland et al., 2005; Luts et al., 2006). The 
CTD contains the majority of the protein binding sites, including sites for hnRNP K, hnRNP D, RBBP6, 
p53, TATA-binding protein among others, as shown in Figure 4 (Eliseeva et al., 2011). Of particular 
interest in Figure 4 is the number of tumour suppressor proteins that interact with YB-1, which again 
highlights its importance in tumourigenesis.   
 
 
Figure 4: Schematic of the protein binding sites on YB-1. Most of the interactions involve the CTD due to the irregular and 
unstructured properties of this domain. Figure taken from Eliseeva et al.(2011). 
1.3.2. Functions and regulation of YB-1 
When YB-1 is localized to the nucleus its functions involve transcription, DNA repair and pre-mRNA 
splicing. YB-1 is a DNA binding protein that was initially identified bound to the promoters of the 
major histocompatibility complex II gene HLA-DRα, as well as the gene encoding the EGF receptor 
enhancer (Didier et al., 1988; Sakura et al., 1988). Binding of YB-1 to these promoter regions was 
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thought to be dependent on the so-called Y-box sequence (5'-CTGATTGGC/TC/TAA-3'). However YB-
1 has since been found to regulate genes without the Y-box sequence in their promoters. YB-1 has 
been described as a nucleic acid chaperone which can melt double-stranded helices in the promoter 
region and bind specifically to pyrimidine-rich strands (Dmitry et al., 2013). This may explain why YB-
1 prefers to bind single-stranded DNA sequences (Izumi et al., 2001). 
Genes that are transcriptionally regulated by YB-1 include genes involved in cell division, apoptosis, 
immune response, multi-drug resistance and tumour growth. In the case of the MDR1 gene which 
encodes the multi-drug resistance protein P-glycoprotein it was originally concluded that 
transduction required binding of YB-1 to the Y-box sequence in the MDR1 promoter (Bargou et al., 
1997). However it was later found that YB-1 binding to the promoter region of MDR1 is dependent 
on it complexing with APE1 protein and histone acetyltransferase p300 as it had a higher affinity for 
MDR1 when in complex with APE1 and p300. (Dmitry et al., 2013). In 2007 Kaszubiak and co-workers 
reported that YB-1 has no effect in MDR1 regulation as the knock down of YB-1 had no effect on P-
glycoprotein or MDR1 mRNA levels or drug sensitivity (Kaszubiak et at., 2007). The involvement of 
YB-1 in MDR1 regulation is therefore still a contentious topic.  On the other hand YB-1 knock-out cell 
lines were sensitive to hypoxia, cisplatin treatment and temperature (Uchiumi et al., 2006). These 
contradictory finding may be cell type-dependent. Taken together these findings establish YB-1 as an 
important regulator of genes involved in cell differentiation, proliferation and stress response. 
YB-1 has a dual function in cell proliferation; at lower concentrations it promotes proliferation 
whereas at higher concentrations it suppresses proliferation. This dual nature was identified when 
YB-1 expression was inhibited by siRNAs which resulted in an increase in cell doubling time and an 
enlarged proportion of cells in the G1-phase (Bergmann et al., 2005). On the other side the 
suppression of YB-1 resulted in a decrease in the amount of cyclin D1 and an increase in 
concentration of cell cycle inhibitors p21 and p16 (Evdokimova et al., 2009). The reason for these 
dual functions is still poorly understood but may also be cell type dependent.   
Combined with its potent function as an activator of proliferation, YB-1 also protects cancer cells 
against apoptosis. It achieves this by binding to the tumour suppressor p53 and hampering p53-
dependent transcription of pro-apoptotic genes APAF1, NOXA and BAX (Lee et al., 2008). Another 
manner in which YB-1 inhibits apoptosis is by suppressing the transcription of the Fas-receptor 
(Homer et al., 2005). 
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The role of YB-1 in stress response is generally dependant on its localisation, either in the nucleus or 
in the cytoplasm. It is generally found in the cytoplasm but translocates to the nucleus upon 
treatment with DNA damaging agents such as xenobiotics or UV irradiation (Dmitry et al., 2013). 
Once localised to the nucleus YB-1 transduces expression of genes that reduce the negative effect of 
these stresses, including MDR1. The exact mechanism of YB-1 translocation has been a highly 
contentious issue. Initially YB-1 was believed to shuttle to the nuclease by complexing with p53 
during genotoxic stress (Lasham et al., 2003). This mechanism was further complicated by the 
findings of Homer and co-workers that functional p53 in required for YB-1 nuclear translocation and 
not simply shuttling (Homer et al., 2005). Furthermore Homer et al (2005) reported that YB‐1 
selectively inhibits the ability of p53 to cause cell death, by preventing transactivation of pro-
apoptotic genes. This YB-1 may be a potential negative regulator of the p53 tumor suppressor. 
Another highly contested mechanism of YB-1 nuclear translocation involves cleavage of YB-1 at 
residue 220 by the 20S proteasome (Sorokin et al., 2005). In 2005 Sorokin and co-workers reported 
that the N-terminal fragment contains a nuclear localisation signal (residues 186-205) and the C-
terminal fragment contains a cytoplasmic retention signal (residues 267-293). Cleavage at residue 
220 releases the N-terminal fragment to translocate to the nuclease, leaving the C-terminal 
fragment in the cytoplasm. Taking all of these proposed mechanisms into account Braithwaite and 
co-workers proposed the scenario for YB-1 translocation shown in Fig 5: upon genotoxic stress YB-1 
is cleaved by the proteasome at residue 220, possibly as a result of phosphorylation at Ser 102. 
Meanwhile p53 is also activated to induce expression of an unknown Protein X which binds to the N-
terminal fragment of YB-1, facilitating translocation of YB-1 to the nucleus and promoting growth 
while inhibiting p53-mediated apoptosis (Braithwaite et al.,2006).  
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Figure 5: The proposed mechanism for YB-1 nuclear translocation. Following  genotoxic stress YB-1 undergoes proteolysis 
following phosphorylation at serine 102. The same stress activates p53 to induce gene X expression which complexes with 
the N-terminal fragment of YB-1, shuttling it to the nucleus.  Taken from Braithwaite et al. (2006) 
In subsequent years the mechanism for YB-1 has been further called into question by the findings of 
Cohen and co-workers, who maintain that cleavage of YB-1 does not take place at all and that the 
whole of YB-1 translocates to the nucleus following cells stress (Cohen et al., 2009). This proposal is 
supported by the findings of Woolley and co-workers that the findings of Sorokin and co-workers 
where influenced by antibody cross-reactivity (Woolley et al., 2011). However more recently van 
Rooyen and colleagues have reiterated that YB-1 undergoes proteolysis at residue 220, but that it is 
the C-terminus, rather than the N-terminus, that translocates to the nucleus (van Rooyen et al., 
2013). The true mechanism of YB-1 translocation and cleavage is therefore still a highly contentious 
issue that requires more investigation.  
Transcription of YB-1 is triggered by the binding of transcription factors GATA1 and GATA2 to the 
GATA-motif, which is a specific sequence within the YB-1 promoter (Yamasaki et al., 2009). 
Transcription factors that bind to the Enhancer-box sequence within the YB-1 promoter include 
Twist or c-Myc and Max (Chen and Behringer. 1995; Uramoto et al., 2002). YB-1 can also be 
ubiquitinated by RBBP6 and FBX33A, resulting in its complete degradation in the 26S proteasome 
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(Lutz et al., 2006; Chibi et al., 2008). On the translational level YB-1 inhibits its own translation by 
binding to its own mRNA within both the 5' and 3' UTRs of YB-1 mRNA (Skabkina et al., 2003). This 
self-inhibition of YB-1 translation is overcome by the binding of PABP within the YB-1 mRNA 
transcript, thereby displacing YB-1 (Skalweit et al., 2003). 
1.4. Murine Double Minute 2 (MDM2) 
MDM2 is a RING finger-containing E3 ligase which is best known as the primary negative regulator of 
the p53 tumour suppressor protein. It was originally discovered as being amplified on double-minute 
chromosomes in transformed mouse fibroblasts (Fakharzadeh et al., 1991). MDM2 binds to p53 and 
ubiquitinates it, resulting in its degradation in the 26S proteasome. In turn, p53 induces the 
transcription of MDM2, leading to a negative feedback loop in which the two proteins suppress each 
other in the absence of genotoxic stress (Weinberg. 2006) (Fig 6).  
 
Figure 6: The p53/Mdm2 negative feedback loop. Under unstressed conditions p53 levels are generally kept low by 
binding Mdm2, which results in the ubiquitination and degradation of p53. But when the cell is under genotoxic stress, p53 
gets post translationally modified (phosphorylation and acetylation), thus not allowing Mdm2 to bind and thus stabilizing 
p53 allowing its levels to rise, to stop the cell cycle or to trigger apoptosis (Appella et al., 2002). Taken from Weinberg 
(2006). 
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Post-translation modifications of both proteins in response to a number of cellular stresses results in 
disruption of the interaction between MDM2 and p53, leading to up-regulation of both (Kruse and 
Gu. 2009). These modifications include phosphorylation and acetylation of p53 (Moll and Petrenko. 
2003). Phosphorylation of MDM2 additionally has the effect of suppressing the E3 ligase activity of 
MDM2 in addition to disrupting its interaction with p53 (Cheng et al., 2011). Abolition of the 
interaction between MDM2 and p53 is considered to be a promising strategy for stabilising and 
activating p53 in tumour cells, and considerable effort has been devoted to understanding the 
structure of the interaction site and designing small molecules for the purpose of disrupting the 
interaction.  Early successes were achieved with Nutlins, a family of molecules which bind to a 
hydrophobic pocket on the N-terminus of MDM2, thereby abolishing the binding of p53 (Bargonetti 
et al., 2008) and the first examples of p53-stabilising drugs designed along these lines have recently 
entered clinical trials. More recently stapled peptides sMTide02 and sMTide2A, which bind to both 
MDM2 and MDMX (see below), were found to be more specific than Nutlins, showed less toxicity to 
p53-negative cells and induced a higher level of p53 reporter gene response than Nutlin in several 
cell-based reporter assays (Hoe et al. 2014). 
Another binding partner of both MDM2 and p53 is MDMX, which is a close homologue of MDM2 
(Linke et al., 2008). MDMX is a RING finger-containing protein but up to now it has not been shown 
to have any E3 ligase activity of its own. Both MDMX and MDM2 form homodimers through their 
respective RING finger domains, but form stronger heterodimers, again through their respective 
RING finger domains. Acting on its own in vitro MDM2 has been shown to be able to catalyse mono-
ubiquitination of p53, but not poly-ubiquitination (Wang et al., 2011). However it has recently been 
reported that the MDMX/MDM2 heterodimer is able to catalyse the poly-ubiquitination of p53, 
resulting in the proteasomal degradation of p53 (Wang et al., 2011).  Strategies aimed at producing 
therapeutics that disrupt the MDM2/MDMX heterodimer are also currently being pursued (Laurie et 
al., 2007). 
1.5. The ubiqutin-conjugating enzyme UbcH1 
1.5.1. Ubiquitin Proteasome System (UPS) 
Ubiquitination is the covalent attachment of ubiquitin to a substrate protein through a number of 
complex, specific and highly-regulated processes (Wolf et al., 2004). It typically requires the 
sequential action of three enzymes: the E1, or ubiquitin-activating enzyme, the E2, or ubiquitin-
conjugating enzyme, and the E3, or ubiquitin-ligase enzyme (Fig 7). The E1 activates the C-terminal 
end of ubiquitin by hydrolysing ATP and using the energy to catalyse the formation of a high-energy 
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thiol-ester bond between its active cysteine and the C-terminal glycine of ubiquitin. The activated 
ubiquitin is then transferred from the E1 to the active site cysteine of the E2 by trans-esterification, 
forming a second thiol-ester linkage with a catalytic cysteine of the E2.  Finally the E3 catalyses the 
transfer of the ubiquitin from the E2 to the substrate, forming an iso-peptide linkage between the C-
terminal glycine of ubiquitin and the Ɛ-amino group of a lysine residue on the substrate (Wolf et al., 
2004).  
 
 
Figure 7: The Ubiquitin Proteasome System.The ubiquitination pathway and proteolysis of a poly-ubiquitinated substrate 
by the 26S proteasome. Taken from Wolf et al,. (2004).   
Ubiquitin itself contains seven lysine residues, at positions 6, 11, 27, 29, 33, 48, and 63. After 
attachment of one ubiquitin monomer to a substrate, additional ubiquitin monomers may attach to 
one of the internal lysines forming a poly-ubiquitin chain (Pickart et al,. 2001). Ubiquitination can 
drastically alter the fate or function of a protein and plays a role in most, if not all, cellular processes. 
The best understood role of poly-ubiquitination is the tagging of substrates for degradation by the 
26S proteasome, which is primarily associated with lysine48-linked chains. These are specifically 
recognised by the 19S cap of the 26S proteasome, leading to recruitment to the proteasome and 
subsequent degradation (Dantuma and Lindsten. 2009). Other linkages, such as those involving only 
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lysine 3, lysine 11 or lysine 63, are associated with DNA repair, endocytosis and the activation of 
protein kinases, but the precise fate of these tags is not yet fully understood (Dantuma and Lindsten. 
2009). 
1.5.2. Structure and function of UbcH1 
UbcH1, which is also known as E2-25K or Huntington interacting protein 2 (Hip2) or by its official 
name UBE2K, is a 22.4 kDa ubiquitin-conjugating (E2) enzyme. It is unusual in its ability to catalyse 
poly-ubiquitination in the absence of an E3 ligase (Haldeman et al,. 1997) and to catalyse the 
formation of free (non-substrate-linked) poly-ubiquitin chains (Helderman et al., 1997). It is also 
unusual in being comprised of a C-terminal ubiquitin associating domain (UBA) in addition to the 
conserved E2 domain (Fig 8). The UBA domain appears to function primarily as a binding partner for 
ubiquitin as in the case of Cb1 E3 ligases (Zhou et al., 2008). 
The 3D structure of UbcH1 has been solved by both crystallography and NMR, as shown in Figure 9 
(Ko et al., 2010). The E2 domain, comprising residues 1-153, consists of a four-stranded β-sheet (β1-
β4), flanked by six alpha helices (α1-α6). The UBA domain, comprising residues 160-200, takes the 
form of a three-helix bundle (α7-α9) and is linked to the E2 by a short tether, residues 154-159.  
 
Figure 8: The domain organisation of UbcH1. A) UbcH1 is a 200 residue protein containing 2 domains: the E2 catalytic 
domain, residues 1-153, and the ubiquitin associated domain, residues 160-200. Adapted from Ko et al. (2010). B) Crystal 
structure of UbcH1 in which the E2 and UBA domains are coloured forest and pale green respectively. Cys-92, Asn-83, and 
Lys-14 (sumoylation site) Ser-86 and Asp-127, which form a hydrogen bond that modulates the active site, are also 
represented. Modified from Ko et al. (2010).  
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UbcH1 has also been reported to bind to the N-terminus of the Huntington protein, implicating it in 
the regulation of Huntington’s disease through the ubiquitin proteasome pathway (Lee et al,. 2001). 
The standard model for the development of neurodegerative diseases like Alzheimer’s and 
Huntington’s involves accumulation of aggressive prion proteins in the brain. In 2003 Song and co-
workers demonstrated, that through its UBA domain, UbcH1 binds a mutant form of ubiquitin 
known as ubiquitin-B (UBB), resulting from a frame-shift mutation.  UBB can’t be degraded in the 
26S proteasome, resulting in the accumulation of UBB-conjugated substrates such as Huntington. Ko 
and colleagues later provided structural support for this mechanism (Ko et al,. 2010). 
In addition to its function as an E2, UbcH1 also plays a role in repair of UV-damaged DNA (Koken et 
al., 1991). Schneider and colleagues later identified UbcH1 as being involved in the repair of 
alkylated and cross-linked DNA (Schneider et al., 1994). In 2013 Bae and colleagues identified UbcH1 
as a direct binding partner for p53. They discovered that after genotoxic stress levels of p53 were 
lower when combined with over-expression of UbcH1 than when UbcH1 was absent. They went on 
to repeat the experiment but blocked the proteasome using MG132 and discovered p53 levels to be 
regulated in a proteasome dependant manner. An in vivo system was used in order to determine 
whether UbcH1 was responsible for the ubiquitination and degradation of p53. An UbcH1 mutant 
(S86Y) was used which is selectively inactivates poly-ubiquitin chain synthesis catalysed by UbcH1 as 
a negative control. In the presence of wild-type UbcH1 p53 was poly-ubiquitinated in the presence 
of MG132 but completely degraded in the absence of MG132. But when wild type UbcH1 was 
replaced by S86Y mutant UbcH1 p53 levels remained stable. This UbcH1 is a potential negative 
regulator of p53 (Bea et al., 2013).  
1.6. Aims and Objectives 
The primary aim of the work described in this thesis was to look for evidence in vitro of direct 
interactions between proteins expected to interact on the basis of their ubiquitination activity; in 
particular for interactions between RBBP6 and YB-1, since we have shown that the R3 fragment of 
RBBP6 is able to ubiquitinate YB-1 in vitro, and between RBBP6 and MDM2, since we have shown 
that R3 is able to ubiquitinate p53 with the assistance of MDM2.  Also between RBBP6 and UbcH1, 
since we have found ubiquitination of YB-1 is optimal with UbcH1 as the ubiquitin-conjugating 
enzyme. 
The interaction between the RING finger domain of RBBP6 and YB-1 had already been localised to 
the final 62 amino acids of YB-1 by Chibi and co-workers, both in yeast 2-hybrid studies and using in 
vitro transcribed/translated proteins (Chibi et al., 2008). The aim here was to try to over-express a 
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larger fragment from the C-terminus of YB-1 containing the 62-residue region, to serve as a model 
system on which to perform a full structural characterisation of the interaction between YB-1 and 
RBBP6 and to study the ubiquitination of YB-1 by RBBP6. Hence the aim was to express a fragment 
of the C-terminus of YB-1 in bacteria, and show that it interacted with the RING finger of RBBP6 in 
vitro. We also aimed to show that the fragment was ubiquitinated by the R3 fragment of RBBP6; 
since the fragment would have a smaller number of lysine residues than full length YB-1, it should be 
possible to replace all but one of the lysines with arginines and in that way determine which lysine 
was the site for attachment of poly-ubiquitin chains. 
In the case of the interaction between RBBP6 and MDM2 a direct interaction was reported by Li and 
co-workers in 2007. The aim of this study was to express the isolated domains of MDM2 and RBBP6 
in bacteria and to conduct pull-down assays which would lay the foundation for future binding 
studies to identify the residues involved in the interaction.  
In the case of RBBP6 and UbcH1 a direct interaction was expected because UbcH1 is able to act as an 
E2 in our ubiquitination assays of YB-1 by RBBP6. The aim of this study was to over-express both 
proteins in bacteria and conduct pulldown assays, followed by NMR-based interaction.  
Questions to be addressed in this thesis include i) Do RBBP6 and YB-1 interact in vitro? Can we 
express a fragment of YB-1 in bacteria suitable for NMR-based structural studies? Can we identify 
amino acid residues involved in the interaction? ii) Can we identify a lysine residue or residues on 
YB-1 to which poly-ubiquitin chains become attached and, if so, can we abolish ubiquitination by 
mutating them to arginines? iii) Do RBBP6 and MDM2 interact in vitro and can we identify amino 
acid residues directly involved in their interaction? iv) Do RBBP6 and UbcH1 interact in vitro and can 
we identify amino acid residues directly involved in their interaction? 
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Chapter 2 
 
Methods and Materials 
 
2.1. Antibodies used 
Anti-RBBP6-RING: 
Rabbit polyclonal custom-raised against residues 249-335 of human RBBP6 in the laboratory of Prof 
Dirk Bellstedt, Department of Biochemistry, University of Stellenbosch.  
Anti-YB-1: 
Rabbit poly-clonal custom-raised against residues 129-324 of YB-1 in the laboratory of Prof Antony 
Braithwaite, University of Sydney, Australia. 
Anti-MDM2: 
Commercial rabbit poly-clonal raised against residues 393-424 of human MDM2, Cat. AB38618  
(Abcam Plc, Cambridge, MA, USA). 
2.2. Bacterial cultures 
2.2.1.  Bacterial strains used 
Escherichia coli strain BL21 (DE3)pLysS: F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) pLysS (CmR). 
chloramphenicol resistant 
This strain was used to express recombinant proteins. Since it contains the lambda DE3 sequence 
integrated into its chromosome (containing the gene for RNA polymerase from phage T7) this strain 
is suitable for expression using the pET family of vectors.  
Escherichia coli strain XL Gold: endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mrcA)183 Δ(mcrCB-
hsdSMR-mrr)173 tetR F’*proAB laclqZΔM15 Tn10(TetR Amy CmR].  
 
 
 
 
21 
 
Allows high-efficiency transformation with large plasmid inserts and was used for cloning. Antibiotic 
resistance against chloramphenicol and tetracycline.  
2.2.2. Antibiotic selection 
Ampicillin, kanamycin or chloramphenicol selection was achieved using concentrations of 100 µg/ml, 
50 μg/ml, 35 µg/ml respectively both in solid and liquid media. 
2.2.3. Bacterial transformation 
Chemically competent cells were thawed on ice and 50 μl were added to 100-500 ng of the plasmid 
DNA solution, gently mixed and incubated for 30 min on ice. The cells were heat shocked by transfer 
to a 42 °C heat block for 90 seconds and incubated again on ice for 2 min, after which 500 μl of pre-
warmed LB broth was added and the mixture incubated at 37 °C shaking for an hour to allow for the 
expression of the antibiotic resistance marker. The transformed cells (100 μl) were then plated onto 
pre-warmed nutrient agar plates containing the appropriate antibiotic and the plates incubated 
overnight at 37 °C. 
2.3. DNA cloning 
2.3.1. Isolation of plasmid DNA 
A single colony of transformed E. coli XL GOLD was inoculated into 5-10 ml of LB containing the 
appropriate antibiotic. The inoculated broth was incubated at 37 °C with vigorous shaking for 16 
hours after which the cells were pelleted by centrifugation at 10000 rpm for 5 minutes in a 
microcentrifuge. Plasmid DNA was isolated using the GeneJET Miniprep kit (Thermo Fisher Scientific, 
Carlsbad, California, United States), according to the manufacturer’s instructions. 
2.3.2.  PCR amplification of gene fragments 
Generally, reactions consisted of 50-100 ng template DNA, 1x PCR buffer, 0.25 mM of each dNTP, 1U 
Taq DNA polymerase and 10 pmol of forward and reverse gene specific oligonucleotides, in a final 
volume of 50 μl. Oligonucleotide melting temperatures (Tm) were calculated using the online tool 
Oligo Calc found at www.basic.northwestern.edu/biotools/oligocalc.html and thermal cycling was 
carried out using the following procedure: 
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95 °C for 2 minutes (Initial denaturation) 
90 °C for 1 min (Denaturation) 
(Tm -5 °C) for 1 min (Annealing) 
72 °C for 1 min/kb (Extension) 
72 °C for 5 min (Final extension) 
2.3.3. Restriction enzyme digestion of DNA 
Restriction enzymes were used according to the manufacturer’s instructions. Generally, 1 μg of 
plasmid DNA or PCR products were digested with 1 unit of the desired restriction enzymes in a 50 μl 
reaction volume containing 1 x buffer. Reactions were incubated at the appropriate temperature for 
1 hour. Digested DNA was analysed by electrophoresis in 1x TBE on 0.8 - 1 % agarose gels.  
2.3.4.  Ligation of DNA 
Vectors used for cloning were prepared as described in Section 2.3.1. Plasmid DNA was digested 
with the appropriate restriction enzymes as described in Section 2.3.3. In general, vectors were 
digested with different enzymes, leaving non-compatible ends. These vectors were used in ligation 
reactions following purification using GeneJET Gel Extraction kit (Thermo Fisher Scientific) to remove 
the restriction enzymes. Generally, 50-100 ng of cloning vectors were used for ligations. Inserts were 
prepared as described in Section 2.3.2. and digested with the same enzymes as in Section 2.3.3. Both 
the cloning vectors and inserts were purified using a GeneJET Gel Extraction kit (Thermo Fisher 
Scientific). Ligations were set up in 20 μl at a vector: insert ratios of 1:3 and 1:5. Each reaction 
volumes contain 1x buffer and 1.0 Weiss unit of T4 ligase. Ligation reactions were allowed to 
proceed at room temperature for 2 hours. This is followed by bacterial transformation as described 
in Section 2.2.3. 
2.3.5. Agarose gel electrophoresis of DNA  
DNA was analysed by electrophoresis on 0.8 or 1% agarose gels. Gels were prepared by adding the 
required volume of 1x TBE to the appropriate mass of electrophoresis grade agarose. The agarose 
was boiled and cooled to 55 °C followed by the addition of GRGreen Nucleic Acid stain 10000x 
(Labgene Scientific, Châtel-St-Denis, Switzerland) to a final concentration of 1x and poured onto a gel 
casting tray. DNA loading buffer was added the DNA to a final concentration of 1x and loaded onto 
the gel. The DNA marker was loaded in the first lane to show the sizes of the bands. The DNA was 
visualized by subjecting the gel to UV light at 365 nm. 
30 
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2.4. Recombinant protein expression 
2.4.1. Protein expression in rich media 
E. coli BL21 (DE) pLysS cells transformed with expression constructs were grown overnight at 37 °C 
on nutrient agar plates containing the appropriate antibiotic. Single colonies were picked and used 
to inoculate 100 ml of LB containing the appropriate antibiotics. This culture was grown overnight at 
37 °C on a rotary shaker. The culture was scaled up to 1 litre by the addition of 900 ml of LB medium 
containing the appropriate antibiotic and grown at 37 °C until the culture reached an optical density 
at 550 nm of 0.5. Recombinant protein expression was induced by the addition of IPTG to a final 
concentration of 0.5 mM. Induction was carried out overnight at 30 °C. Overnight cultures were 
transferred to 250 ml polypropylene tubes and the cells harvested by centrifugation at 6000 rpm for 
30 minutes at 4 °C. 
2.4.2.  Protein expression in labelled media 
For 15N labelling of recombinant protein, proteins were expressed in minimal medium (see Table 2.1) 
supplemented with 18.7 mM 15N-NH4Cl (Cambridge Isotope Laboratories, Inc., Tewksbury, MA, USA) 
as the sole nitrogen source. Expression was carried out as described in Section 2.4.1.  
2.5. Protein purification 
2.5.1. Protein extraction  
Cell pellets were thawed on ice and resuspended in extraction buffer for the purification of 6xHis 
fusion proteins, the extraction buffer was supplemented with 40 mM imidazole (Table 2.1). After 
which they were lysed on ice by sonication, which was carried out in 30 second bursts, followed by 
30 seconds rest on ice, repeated for 5 minutes. The lysate was cleared by centrifugation at 14000 
rpm for 30 minutes at 4 °C. 
2.5.2. Affinity purification 
A disposable plastic column containing 5 ml of the appropriate media (glutathione agarose or nickel 
sepharose) was washed with 3 column volumes (CV) of 8 M urea, 5 CV of water, 3 CV of 100 mM 
acetate buffer pH 4.5, 3 CV 100 mM borate buffer pH 8.5 and then equilibrated with 5 CV of wash 
buffer (see Table 2.1). The crude lysate was added to the column and the flow through collected 
after which the column was washed with 3 CV of wash buffer and each CV collected. The bound 
proteins were then eluted with the appropriate buffer: in the case of GST fusion proteins, the elution 
buffer contained 20 mM reduced glutathione, while 500 mM imidazole was used to elute 6xHis 
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tagged proteins. Finally, the column was washed and stored in 1 M NaCl containing 0.2 % NaN3. 
Purified fractions were analysed by SDS-PAGE. 
2.5.3. Cleavage of recombinant protein 
3C protease from human rhinovirus was expressed in the laboratory as a GST-fusion protein and 
purified as described in Sections 2.4 and 2.5. GST-fusion proteins were cleaved with 3C protease in a 
SnakeskinTM dialysis bag (Thermo Fisher Scientific) with a 3.5 kDa MWCO. The tubing was then 
placed in 2 L of cleavage buffer in a 5 L beaker at 4 °C overnight with stirring. Following cleavage the 
GST tag and the GST-3C was separated from the target protein by returning the cleaved sample to a 
glutathione agarose column as described in Section 2.5.2. The target protein was collected in the 
flow-through with the cleaved GST, the uncleaved GST-fusion and GST-3C remaining immobilised on 
the column. 
2.5.4. Size exclusion chromatography 
Protein samples were concentrated into 0.5 - 1 ml and then loaded onto a calibrated Superdex 75 
16/600 column (Amersham Biosciences, Pittsburgh, USA), operated on an ÄKTA FPLC 
chromatography platform (GE Healthcare, Little Chalfont, UK). 2 ml elution fractions were collected 
for a total elution volume of 1 CV.   
2.5.5.  HisTRAP affinity chromatography 
6xHis tagged proteins were loaded onto a 5 ml HisTRAP column (GE Healthcare, Little Chalfont, UK) 
operated on an ÄKTA FPLC chromatography system equilibrated with 3 CV of wash buffer. The 
column was washed with 4 CV of wash buffer and the bound protein was eluted using a 0 - 500 mM 
concentration gradient of imidazole and collected in 2 ml fractions. 
2.6. SDS-PAGE gel electrophoresis 
Proteins were fractionated on 16 % denaturing polyacrylamide gels (SDS-PAGE) prepared using 
Laemmli’s method (Laemmli, 1970).  Gel was prepared as follows: 
Resolving gel 16 % Stacking gel 4 % 
1.6 ml dH2O 1.5 ml dH2O 
1.3 ml Separating buffer 0.625 ml Stacking buffer 
2 ml acrylamide (40% acrylamide:bis-acrylamide) 0.375 ml acrylamide (40 % acrylamide:bis-
acrylamide) 
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52.4 µl 10 % SDS 25 µl 10 % SDS 
30 µl 10 % APS 12.5 µl APS 
3.75 µl TEMED 2.5 µl TEMED 
 
Samples were prepared by adding equal volumes of sample and 2x SDS sample buffer and boiling at 
95 °C for 10 minutes. Samples were then loaded onto the gel and separated using a Mini-PROTEAN 
Tetra Cell (BioRAD, Hercules, CA, USA). Upon completion the gel was stained with Coomasie staining 
solution for 15 minutes and destained with destaining solution until the background was clear. 
2.7. Immuno-detection of proteins  
Following separation on SDS-PAGE as described in Section 2.6, proteins were transferred onto PVDF 
membrane (0.2 µm Immun-Blot, BioRAD, BioRad, Hercules, CA, USA) using the Trans-Blot® Turbo™ 
Transfer System (BioRad) in transfer buffer (see Table 2.1). Following transfer non-specific binding 
was blocked by incubating the membrane in 1 % casein in PBS-T for 1 hour at room temperature 
with shaking. This was followed by incubation with primary antibodies for 1 hour at room 
temperature with shaking. The membrane was then washed for 3 x 10 minutes with PBS-T following 
which it was incubated with secondary antibodies for 1 hour at room temperature with shaking. The 
membrane was then washed for 3 x 10 minutes with PBS-T. The blot was then developed in ClarityTM 
ECL Western Blotting Substrate (BioRad) and visualized on the ChemiDoc system from UVP (Nuffield 
road, Cambridge UK). 
2.8. Affinity pull-down assays 
GST pull-down assays were performed using GST-tagged “bait” and un-tagged “prey” proteins. Equal 
molar quantities of GST-tagged bait proteins or GST (to serve as negative control) were added to 20 
μl of 50 % glutathione agarose slurry. Equal amounts of prey were added to both baits and 
incubated overnight at 4 °C with rolling. An additional negative control was included from which the 
bait protein was omitted altogether. The beads were pelleted by centrifugation and washed 3 times 
with 1 ml wash buffer. Finally the beads were re-suspended in 40 μl of SDS sample buffer, boiled for 
5 minutes at 95 °C and 10 µl loaded onto an SDS-PAGE gel. Prey proteins were immuno-detected 
with the appropriate antibodies as described above. 
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2.9. Co-immunoprecipitation   
Co-immunoprecipitation assays were conducted in a similar manner as GST pull-down assays, with 
the exception that bait proteins were precipitated using antibodies conjugated to agarose, which 
were themselves precipitated with Protein A/G-conjugated agarose. Protein A/G is a protein with 
high affinity for immunoglobulin molecules such as the primary antibodies targeting the bait protein. 
In this case both the bait and prey proteins were present in mammalian cell lysates. 100 µg of each 
lysate was mixed with 20 μl Protein A/G-conjugated antibodies against one of the proteins of 
interest which were then incubated overnight at 4 °C with rolling. The beads were pelleted by 
centrifugation and washed 3 times with 1 ml wash buffer. Finally the beads were resuspended in 30 
μl sample buffer, boiled for 5 minutes at 95 °C and 10 μl separated on 16% SDS-PAGE gels. 
Precipitated proteins were immunodetected with the appropriate antibodies as described before. 
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Chapter 3 
 
Investigation of interactions involved in the 
regulation of YB-1 by RBBP6 
3.1. Introduction 
The RING finger domain of Retinoblastoma Binding Protein 6 has previously been shown in a yeast 2-
hybrid assay to interact directly with the C-terminal 62-amino acids of Y-Box Binding Protein-1 (Chibi 
et al., 2008). Chibi and co-workers went on to confirm the interaction by expressing the two regions 
in an in vitro transcription/translation system and conducting immunoprecipitation assays. 
Subsequent attempts to express the relevant fragment of YB-1, residues 262-324, at larger scale in 
bacteria proved unsuccessful due to poor solubility (Victor Muleya, MSc thesis, UWC, 2011). In this 
work we set out to identify a larger fragment of the C-terminus of YB-1 that would be suitable for 
large-scale expression in bacteria and subsequent NMR-based interaction studies, with the aim of 
identifying residues directly involved in the interaction.  
The region of YB-1 spanning residues 220-324, denoted YB-1220-324, was selected since this fragment 
corresponds to the C-terminal fragment reportedly released from YB-1 by proteasomal cleavage 
(Sorokin et al., 2005; van Rooyen et al., 2013), suggesting that it may be independently folding and 
resistant to proteolysis. With a molecular mass of 12.5 kDa, YB-1220-324 would be the ideal size for 
NMR-based interaction studies and for structure determination. Since YB-1 is known to form 
oligomers (Evdokimova et al., 1995), which give rise to high backgrounds in in vitro ubiquitination 
assays, it was hoped that the fragment would serve as a “cleaner” substitute for YB-1 in these 
assays. The selected fragment corresponds to approximately half of the C-terminus, making it 
possible that the reduced numbers of the charges may render it less likely to oligomerise. 
Investigating ubiquitination using a smaller fragment may also aid in identifying the target lysine, 
since with only four lysines in YB-1220-324 as opposed to the sixteen in full length YB-1, systematic 
mutation of individual lysines to arginine becomes feasible. 
This chapter describes bacterial expression and purification of YB-1220-324 with an N-terminal GST and 
a C-terminal 6xHis tag, followed by affinity pulldown assays aimed a co-precipitating the isolated 
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RING finger domain of RBBP6 (RBBP6-RING). The latter was used since it was the domain originally 
shown to interact with YB-1 in yeast 2-hybrid assays (Chibi et al., 2008). Furthermore RBBP6-RING is 
known to be suitable for large-scale expression in bacteria and its 15N-HSQC NMR spectrum has been 
previously assigned and published (Kappo et al., 2012), which would allow for immediate 
identification of resonances perturbed during binding. A hemagglutinin tag (HA) was included 
between the GST tag and YB-1220-324 for future immunodetection using anti-HA antibodies. However 
the HA tag was not used in this study as antibodies recognising YB-1220-324 and RBBP6-RING were 
used instead. 
The chapter continues by describing in vitro investigations of two interactions which are suggested 
by unpublished results generated by other members of our laboratory. These are the putative 
interaction of RBBP6-RING with the ubiquitin-conjugating enzyme UbcH1, which is suggested by Dr 
Andrew Faro’s finding that RBBP6 catalyses poly-ubiquitination of YB-1 using UbcH1 as E2 (A. Faro 
and D.J.R. Pugh, manuscript in preparation). The second putative interaction involves RBBP6-RING 
and the oncogenic protein Murine Double Minute 2 (MDM2), which is suggested by Ms Lauren 
Jooste’s finding that RBBP6 cooperates with MDM2 in ubiquitinating p53 in vitro (L. Jooste, A. Faro 
and D.J.R. Pugh, manuscript in preparation).  If verified this result would confirm and extend the 
report of Li and co-workers that RBBP6 cooperates with MDM2 in vivo to suppress levels of p53 
during development (Li et al., 2007).  The above two studies are preliminary studies aimed at 
establishing optimal conditions for future, more focussed, investigations using Nuclear Magnetic 
Resonance spectroscopy (NMR). 
The chapter begins with description of a side-project whose aim was to generate a bacterial 
expression construct coding for the DWNN domain from RBBP6, terminating immediately following 
the di-glycine (-GG) motif which represents a key feature of vertebrate DWNN domains. This motif is 
found at exactly the same structural position as the di-glycine motif in ubiquitin, raising the 
possibility that the DWNN domain becomes covalently attached to substrate proteins in a process 
which has been dubbed “DWNNylation”. Before it can be attached to substrate proteins in vivo 
ubiquitin is enzymatically processed to expose the –GG motif and recombinant ubiquitin used in in 
vitro ubiquitination assays is designed to terminate immediately following the –GG.  The aim was 
therefore to produce an expression construct encoding DWNN-GG for use by co-workers conducting 
DWNNylation assays. An HA tag was included immediately upstream of DWNN-GG for 
immunodetection using anti-HA antibodies; the construct was designed in such as way that it could 
be re-used to generate HA-tagged versions of existing constructs cloned into pGEX-6P-2. 
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3.2. Generation of a GST-HA-DWNN-GG expression construct 
 
3.2.1.  Cloning of HA-DWNN-GG into pGEX-6P-2 
 
The first task was to modify the pGEX-6P-2 expression vector to insert a hemagglutinin (HA) 
immunotag between the 3C protease site and the multiple cloning cassette (MCC), at the same time 
as inserting the cDNA coding for DWNN-GG between the BamHI and XhoI sites of the MCC.  This was 
done by amplifying HA-BamHI-DWNN-GG flanked by 5’-BglII and 3’-XhoI sites and cloning it into the 
BamHI/XhoI sites of pGEX-6P-2, as described in Section 2.3. Since BglII and BamHI produce 
compatible overhangs, the BglII/BamHI site would be destroyed whereas the internal BamHI site 
would be preserved, regenerating the MCC downstream of the BglII site.  This was done so that the 
DWNN domain could later be excised and replaced with any other cDNA previously cloned into the 
BamHI/XhoI sites of pGEX-6P-2. This latter feature was exploited below for generation of the GST-
HA-YB-1220-334-6xHis construct.  
 
Figure 3.1: Construct map of pGEX-HA-DWNN-GG. pGEX-6P-2 vector with the GST (Purple) fused HA-DWNN-GG (HA-tag 
red and DWNN-GG in yellow) gene separated by a HRV 3C cleavage site (Red).  
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atgtacccatacgatgttccagattacgctgcgggatccatgtcctgtgtgcattataaa 
 M  Y  P  Y  D  V  P  D  Y  A  A  G  S  M  S  C  V  H  Y  K  
ttttcctctaaactcaactatgataccgtcacctttgatgggctccacatctccctctgc 
 F  S  S  K  L  N  Y  D  T  V  T  F  D  G  L  H  I  S  L  C  
gacttaaagaagcagattatggggagagagaagctgaaagctgccgactgcgacctgcag 
 D  L  K  K  Q  I  M  G  R  E  K  L  K  A  A  D  C  D  L  Q  
atcaccaatgcgcagacgaaagaagaatatactgatgataatgctctgattcctaagaat 
 I  T  N  A  Q  T  K  E  E  Y  T  D  D  N  A  L  I  P  K  N  
tcttctgtaattgttagaagaattcctattggaggt 
 S  S  V  I  V  R  R  I  P  I  G  G  
  
Figure 3.2: DNA sequence and amino acid translation of HA-DWNN-GG. DWNN comprises residues 1-79 of RBBP6, 
terminating after the –GG motif highlighted in yellow, BamHI indicated in turquoise and HA tag in red. 
  
The primers are shown in Table 3.1. The reverse primer contains two stop codons (5’-TGA|TGA) 
immediately preceding the XhoI site (green); the underlined bases are complimentary to the 
template. The forward primer contains the sequence coding for the HA tag, highlighted in purple, 
flanked by BglII (yellow) and BamHI (turquoise) sites at the 5’- and 3’-ends respectively. Following 
amplification and cloning into the BamHI and XhoI sites of the pGEX-6P-2 expression vector, the 
BamHI/BglII sites were both destroyed, leaving the internal BamHI site on the 3’-end of the HA tag. 
This allowed the DWNN-GG domain to be subsequently excised with BamHI and XhoI and replaced 
with any other BamHI/XhoI fragment. An existing pGEX-6P-2 construct encoding residues 1-118 of 
RBBP6 was used as the template. 
Table 3.1: Oligonucleotides used to amplify the HA-DWNN-GG fragment. The HA tag is shown in purple and the restriction 
enzymes sites in yellow (Bgl II), blue (BamHI) purple and green (XhoI). Two stop codons are shown in red. Underlines bases 
are complimentary to the template. 
Primer name Primer sequence Primer melting temperature 
Forward primer 5’- GAG GCGAGA TCTATG TAC CCA 
TAC GAT GTT CCA GAT TAC GCT 
GCG GGA TCC ATG TCC TGT GTG CA 
-3’ 
62 oC 
Reverse primer 5’-GAG GCGCTC GAGTCA TCA ACC 
TCC AAT AGG AAT TCT TCTAA -3’ 
62 oC 
 
As can be seen in Figure 3.3(A), the HA-DWNN-GG fragment was successfully amplified as a 294 bp 
amplicon (lane 2) The amplicon was digested with BglII and XhoI restriction enzymes (Thermo Fisher 
Scientific) and cloned into the BamHI and XhoI sites of the pGEX-6p-2 vector. Putative positive clones 
were screened by colony-PCR using the HA-DWNN-GG-specific primers shown in Table 3.1 (see Fig 
3.3 B), and by extraction of plasmid DNA followed by restriction digest with BamHI and XhoI to 
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release an insert of approximately 294 bp (Fig 3.3 C). The DNA sequences of positive clones were 
confirmed by DNA sequencing at Inqaba Biotechnical Industries (Pty) Ltd (Hatfield, South Africa) and 
found to be 100 % in agreement with the expected sequence (Appendix).  
 
 
 
Figure 3.3: Successful cloning of HA-DWNN-GG into pGEX-p6-2. (A) The HA-DWNN-GG fragment was amplified from the 
pGEX-6P-2-RBBP6-DWNN construct.  Lane 2 contains a ~294 bp band which corresponds to the HA-DWNN-GG amplicon 
size. (B) Putative positive colonies were screened using colony-PCR and amplified a band of the expected size of ~294 bp 
(lanes 3 and 4) Lane 2 contains negative control to which no template DNA was added. (C) Screening of colonies testing 
positive using colony-PCR was digested with BamH I and Xho I. The release of a fragment of 294 bp (lanes 3 and 4) confirm 
that the cloning was successfully carried out.  
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3.2.2. Expression and purification of HA-DWNN-GG 
 
HA-DWNN-GG was expressed solubly as a GST-fusion protein in E. coli BL21 cells and purified away 
from cellular proteins using glutathione-affinity chromatography, as described in Section 2.5. GST-
HA-DWNN-GG migrated on 16 % SDS-PAGE at the expected size of 40 kDa, as can be seen as seen in 
lanes 6-9 of Fig 3.4(A). 
 
 
 
Figure 3.4.: Purification of HA-DWNN-GG. (A) GST-HA-DWNN-GG was purified using a glutathione agarose column. Lanes 
5-9 contain 40 kDa bands which correspond to the expected size of GST-HA-DWNN-GG. (B) Following cleavage with 3C 
protease, HA-DWNN-GG was purified away from GAT using a second round of glutathione affinity chromatography (data 
not shown) and finally using size exclusion chromatography on a calibrated Hiload Superdex 75 16/600 SEC column. (C) SEC 
yielded two well-separated peaks which turned out to be HA-DWNN-GG (lanes 6-9) and GST (lane 2). 
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Eluted fractions were pooled and incubated overnight at 4 oC with 3C protease to cleave the GST tag 
using the protease recognition site incorporated into the vector between GST and the HA tag. The 
sample was simultaneously dialysed to remove free glutathione. The cleaved sample was subjected 
to a second round of glutathione affinity chromatography to remove cleaved GST, uncleaved fusion 
and GST-3C protease, and the target protein was collected in the flow through. Residual GST was 
removed using size exclusion chromatography on the ÄKTA FPLC chromatography system using a 
calibrated Hiload Superdex 75 16/600 SEC column (GE Healthcare, Little Chalfont. UK). Fractions 
corresponding to the peaks in the resulting chromatogram were analysed on SDS PAGE, as shown in 
Fig 3.4(B). HA-DWNN-GG, with a molecular weight of 14 kDa (lanes 4-9), was well separated from 
GST (26 kDa) (lane 2), yielding a highly purified sample of HA-DWNN-GG.  
 
3.3. RBBP6 interacts with YB-1 in mammalian cell lysates 
 
3.3.1. Co-immunoprecipitation of YB-1 by RBBP6 
 
Prior to attempting to localise the interaction between RBBP6 and YB-1 in vitro, we first attempted 
to reproduce the reported interaction between endogenous RBBP6 and YB-1 in mammalian cell 
lysates. We began by investigating whether endogenous RBBP6 was able to precipitate full length 
YB-1 from HeLa cell lysate. Immunoprecipitation was carried out using 100 µg lysate and a rabbit 
poly-clonal antibody raised against bacterially-expressed RBBP6-RING. As a negative control the anti-
RBBP6-RING antibody was replaced with an anti-HA antibody. Following immunoprecipitation and 
extensive washing the samples were resuspended in 30 µl sample buffer and 15 µl separated on 
SDS-PAGE and detected using a poly-clonal antibody raised against residues 129-324 of YB-1. Details 
of the antibodies used are provided in 2.1. The positive control (lane 2), which was not subjected to 
immunoprecipitation, contains a fifth of the lysate used in the immunoprecipitation. 
Lane 4 of Figure 3.5 shows that the anti-RBBP6 antibody was able to co-precipitate a protein at 
approximately 50 kDa, which is consistent with full-length endogenous YB-1, whereas the anti-HA 
antibody in lane 3 was not. The anti-RBBP6 antibody also co-precipitated a fragment of between 20 
and 30 kDa which, since the antibody targets an antigen on the C-terminus of YB-1, is most likely to 
correspond to a C-terminal isoform or degradation fragment of YB-1. This is consistent with previous 
reports that RBBP6 interacts with the C-terminus of YB-1 (Chibi et al., 2008). Both co-precipitated 
bands are visible in the non-precipitated lysate following longer exposure (lane 2, panel (B), which 
corresponds to the dotted area in panel A), which is as expected. 
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The amount of lysate added to the immunoprecipitation in lane 4 was five times that loaded in lane 
2, but only 15 μl out of the of the final resuspended volume of 30 μl was loaded; hence if all of the 
YB-1 added to the immunoprecipitation in lane 4 were co-immunoprecipitated, we should expect a 
relative intensity of lane 4 relative to lane 2 of 2.5. The band in lane 4 is already weak, but no band is 
visible in lane 2, so the intensity looks somewhat more than 2.5-fold less. On the other hand a band 
is visible in panel B, which was subjected to 50 s of exposure, compared to 5 s for panel (A), which 
represents a 10-fold sensitivity enhancement. Hence if all of the YB-1 added to the 
immunoprecipitation in lane 4 were co-immunoprecipitated, we should expect an intensity of the 
bands in panel B to be 10/2.5 = 4 times more intense than those in lane 4 of panel A. While 
quantifying the relative intensity is difficult, it does appear to be consistent with 4, in which case we 
may suspect that the interaction between endogenous RBBP6 and YB-1 is fairly strong.  
 
 
Figure 3.5: Endogenous RBBP6 is able to co-precipitate endogenous YB-1. (A) Western blot detected using an antibody 
raised against the C-terminus of YB-1. Equal amount of HeLa lysate was added to lanes 3 and 4. An antibody raised against 
RBBP6-RING is able to precipitate endogenous YB-1 (lane 4), whereas a non-specific antibody (anti-HA) is not (lane 3). The 
band at 50 kDa is consistent with full length YB-1. The band between 20 and 30 kDa is likely to be either a C-terminal 
isoform of YB-1 or else a C-terminal degradation product, since the antibody recognises the C-terminus of YB-1. Lane 2 
contains lysate only and was not subjected to immunoprecipitation. Although endogenous YB-1 is not visible in lane 2, it is 
visible when the western blot is exposed for ten times longer, as shown in panel (B). 
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3.4. The RING finger of RBBP6 interacts with the CTD of YB-1 in vitro 
 
3.4.1. Expression and purification of the RING finger domain from RBBP6 
 
Having verified the interaction between endogenous full length YB-1 and RBBP6, we next 
investigated the interaction between smaller fragments in vitro: the RING finger domain of RBBP6 
and the C-terminal fragment of YB-1, YB-1220-324. The RING finger domain, RBBP6249-335, was selected 
because it was the fragment used in the yeast 2-hybrid assay which originally identified YB-1 as an 
interaction partner of RBBP6 (Chibi et al., 2008). The RING finger has subsequently been shown to 
express solubly in high quantities and to be suitable for NMR interaction studies (Kappo et al., 2012). 
Furthermore the 15N-HSQC NMR spectrum of RBBP6-RING has been fully assigned, which means that 
NMR resonances found to be perturbed during binding can be immediately assigned to residues in 
the domain, allowing mapping of the interaction surface.  
A pGEX-6P-2 expression construct for RBBP6249-335 was already available in the laboratory. The 
domain was expressed as a fusion with GST and purified using glutathione affinity chromatography. 
GST-RBBP6-RING was found to migrate at the expected size of 37 kDa, as seen in the eluted fractions 
(Fig. 3.6(A), lanes 6-9). The GST tag was removed using 3C protease and separated from RBBP6-RING 
using size exclusion chromatography, as shown in panels (B) and (C). SDS-PAGE analysis showed that 
RBBP6-RING, which has a molecular weight of 10.2 kDa (lanes 4-8), was very efficiently separated 
from GST (26 kDa, lane 2) and from a number of higher molecular weight contaminants apparent in 
lane 10. The apparent molecular weight of RBBP6-RING (around 15 kDa) is somewhat higher than 
expected for a 10 kDa protein, but this is consistent with earlier reports (Kappo et al, 2012).  
For NMR studies the RBBP6 RING finger domain was successfully expressed as a 15N-labelled protein 
by expressing it in M9 minimal media supplemented with 15N ammonium chloride as the sole 
nitrogen source (Cambridge Isotope Laboratories, Inc., Cambridge, Mass, USA), as described in 
Section 2.4.2. 15N-labelled GST-RBBP6-RING was solubility expressed (Fig 3.7 A) and purified using 
glutathione affinity chromatography, as shown in Fig. 3.7(A), lanes 6-9. Following cleavage with 3C 
protease 15N-RBBP6-RING was successfully separated from GST using size exclusion chromatography, 
as shown in panel (B), lanes 4-10. As with unlabelled RBBP6-RING, the protein migrates as a smear 
around 15 kDa.  Fractions containing 15N-RBBP6-RING fractions were pooled and concentrated to 
150 μM, which is considered adequate for NMR chemical shift perturbation studies. 
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Figure 3.2.: Purification of the RBBP6 RING finger domain. (A) RBBP6 RING finger domain was purified using a glutathione 
agarose column. Lanes 6-9 contain 37 kDa bands which correspond to the expected size of GST-RBBP6 RING. The purified 
protein was then cleaved with recombinant 3C protease. (B) Following cleavage concentrated RBBP6 RING was further 
purified using Size Exclusion Chromatography on a calibrated Hiload Superdex 75 16/600 SEC column. (C)Lane 10 contains a 
concentrated sample which was loaded on the column and contained three major bands 37 kDa, 26 kDa and 15 kDa 
corresponding to GST-RING, GST and the RBBP6 RING finger respectively. Lane 2 correspond to the fraction were GST 
eluted and Lanes 4-8 contain the fractions where the RBBP6 RING eluted.  
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Figure 3.7: Purification of 
15
N-labelled RBBP6-RING finger domain. (A) RBBP6 RING finger domain was purified using a 
glutathione agarose column. Lanes 6-9 contain 37 kDa bands which correspond to the expected size of GST-RBBP6 RING. 
(B) Following cleavage concentrated RBBP6 RING was further purified using Size Exclusion Chromatography. Lane 1 
contained a concentrated sample containing GST and the RBBP6 RING finger. Lane 3 contain the fraction were GST was 
eluted and Lanes 4-9 contain the fractions were the RBBP6 RING finger domain eluted.  
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3.4.2. Cloning of wild type YB-1220-324 for expression in bacteria 
 
The region of YB-1 selected for in vitro studies was residues 220 – 324, dubbed YB-1220-324 (Fig 3.8). As 
described earlier this includes the 62-residue region identified in a yeast 2-hybrid screen as 
interacting with the RING finger of RBBP6 (Chibi et al., 2008). It also coincides with the C-terminal 
fragment reported to be separated from full length YB-1 by cleavage in the proteasome (Sorokin et 
al, 2005; van Rooyen et al., 2013), and hence characterising its expression would lay the groundwork 
for future structural and functional studies on the fragment. 
 
 
 
Figure 3.8: Construct map of pGEX-HA-YB-1220-324 -6xHis. pGEX-6P-2 vector with the GST (Purple)-fused HA-YB-1220-324-
6xHis (HA-tag light purple, YB-1220-324  in oranje and 6xHis-tag in brown light purple) gene separated by a HRV 3C cleavage 
site (purple). 
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gggcccctgggatctatgtacccatacgatgttccagattacgctgcgggatccggtgct 
 G  P  L  G  S  M  Y  P  Y  D  V  P  D  Y  A  A  G  S  G  A  
gacaaccagggtgcaggagaacaaggtagaccagtgaggcagaatatgtatcggggatat 
 D  N  Q  G  A  G  E  Q  G  R  P  V  R  Q  N  M  Y  R  G  Y  
agaccacgattccgcaggggccctcctcgccaaagacagcctagagaggacggcaatgaa 
 R  P  R  F  R  R  G  P  P  R  Q  R  Q  P  R  E  D  G  N  E  
gaagataaagaaaatcaaggagatgagacccaaggtcagcagccacctcaacgtcggtac 
 E  D  K  E  N  Q  G  D  E  T  Q  G  Q  Q  P  P  Q  R  R  Y  
cgccgcaacttcaattaccgacgcagacgcccagaaaaccctaaaccacaagatggcaaa 
 R  R  N  F  N  Y  R  R  R  R  P  E  N  P  K  P  Q  D  G  K  
gagacaaaagcagccgatccaccagctgagaattcgtccgctcccgaggctgagcagggc 
 E  T  K  A  A  D  P  P  A  E  N  S  S  A  P  E  A  E  Q  G  
ggggctgagcatcatcatcatcatcat 
 G  A  E  H  H  H  H  H  H 
Figure 3.9: DNA sequence and mRNA translation of HA-YB-1220-324. YB-1220-324 comprises residues 220-324 of YB-1 followed 
by a 6xHis tag. HA tag indicated in red and 6xHis tag indicated in green. The four lysines are indicated in yellow. BamHI and 
XhoI sites (turquoise and red respectively) were added to the ends to facilitate cloning into the same sites in the vector. 
The significance of the KpnI site (GGTACC – indicated in blue) is explained below. 
 
The fragment was amplified from full length YB-1 using the primers shown in Table 3.2 and cloned 
into the pGEX-HA-DWNN-GG construct described above, following excision of the DWNN-GG with 
BamHI and XhoI. Because YB-1 had previously been seen to be susceptible to degradation from the 
C-terminus a 6His tag was incorporated into the reverse primer (shown in green), to facilitate 
purification of full length YB-1220-324 and not degradation products. The amino acid sequence of the 
protein following removal of GST is shown in Figure 3.9.  
Table 3.2: Oligonucleotides used to amplify the YB-1220-324 fragment. The restriction enzymes sites are coloured (BamHI 
turquoise and XhoI red) and 6xHis in green. What do the underlined bps signifiy? Where is the underlining in the forward 
primer? 
Primer name Primer sequence Primer melting temperature 
Forward primer 5’- GAG GCGGGA TCCGGT GCT 
GAC AAC CAG GGT G -3’ 
62 oC 
Reverse primer 5’-GAG GCGCTC GAG TTA ATG 
ATG ATG ATG ATG ATG CTC AGC 
CCC GCC CTG CTC-3’ 
64 oC 
 
A 348 bp amplicon corresponding to YB-1220-324 was successfully amplified using full length YB-1 as 
template, as shown in lane 3 of Figure 3.10(A). The amplicon was digested with BamHI and XhoI and 
cloned into the pGEX-HA-DWNN-GG vector following excision of the DWNN-GG fragment with the 
same restriction enzymes. Putative positive clones were screened by colony-PCR using the primers in 
Table 3.2 and confirmed by digestion of plasmid DNA to release the insert, as shown in Figure 3.10, 
panels (B) and (C). Positive clones were confirmed by DNA sequencing (Inqaba Biotechnical 
Industries (Pty) Ltd) and found to be 100 % in agreement with the expected sequence (Appendix). 
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Figure 3.10: Cloning of wild type YB-1220-324 into pGEX-HA-DWNN-GG. (A) The YB-1220-324 fragment was amplified from the 
pGEX-YB-1FL construct.  Lane 3 contains a 348 bp band which corresponds to the YB-1220-324 amplicon size. Lane 2 contains a 
no template DNA control which is negative containing only primer dimers. (B) Putative positive colonies were screened 
using colony-PCR. Lanes 2 and 3 contained negative controls in which no template DNA and a no-insert colony were used 
respectively.  Lanes 4-19 contain amplicons of putative positive colonies. (C) Screening of positive colonies by digesting 
with BamHI and XhoI to release the YB-1220-324 insert. Lanes 2-5 all contain a 348 bp insert corresponding to YB-1220-324. 
 
 
 
 
41 
 
3.4.3. Cloning of YB-1220-324-RRRR and -RKKK mutants  
 
Another motivation for cloning of the YB-1220-324 fragment was the hope that it would serve as a well-
behaved substrate for in vitro ubiquitination studies of YB-1 by RBBP6. Full length YB-1 has been 
shown by Dr Andrew Faro, a co-worker in the laboratory, to be poly-ubiquitinated by RBBP6 in vitro. 
Since RBBP6 is known to interact with the C-terminus of YB-1, we expected that YB-1220-324 would 
also be ubiquitinated by RBBP6. YB-1220-324 contains only four lysines (see Fig 3.9) rather than the 
sixteen in full length YB-1, making it feasible to replace them individually with arginines in order to 
determine if ubiquitination was taking place exclusively on any one of them.  
 
 
 
Figure 3.11: Sub-cloning of YB-1220-324-RRRR mutant into pGEX-HA-DWNN-GG. (A) YB-1220-324-RRRR mutant was sub-cloned 
from a pUC57 vector into a pGEX-6p-2-HA vector (pGEX-HA-ΔDWNN-GG). Lanes 2 and 3 contain the pGEX-HA-DWNN-GG 
vector digested with BamHI and XhoI releasing the DWNN-GG insert 232 bp and the pGEX-HA vector 5.7 kb. Lanes 5 and 6 
contain the pUC57 YB-1220-324-RRRR mutant construct digested with BamHI and XhoI releasing the YB-1220-324-RRRR mutant 
348 bp. (B) Screening of putative positive colonies using colony pcr. Lane 2 and 3 contains no template DNA and 
background negative colony controls. Lanes 3-9 contain amplicons of the expected size of YB-1220-324-RRRR 348 bp. 
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We began by replacing all four lysines with arginines, since this would serve as a useful negative 
control for ubiquitination of wild type YB-1220-324. The construct was dubbed YB-1220-324-RRRR, to 
distinguish it from YB-1220-324-KKKK, which is better known as wild type YB-1220-324. To save time YB-
1220-324-RRRR, flanked by BamHI and XhoI sites and incorporating the C-terminal 6xHis tag also 
present in wild type YB-1220-324, was synthesised by Genscript Inc. (Piscataway, NJ, USA) and 
delivered in a pUC57 plasmid. The insert was released using BamHI and XhoI (Fig 3.11(A), lanes 5-6) 
and sub-cloned into the pGEX-HA-DWNN-GG plasmid following excision of DWNN-GG (Fig 3.11(A), 
lanes 2-3). Putative positive clones were screened by colony-PCR using the primers in Table 3.2, as 
shown in Figure 3.11(B). The sequences were verified by direct sequencing and found to be 100 % in 
agreement with the expected sequence, including replacement of codon AAA, corresponding to 
lysine, with CGC, corresponding to arginine, in four places (Appendix). 
 
The next step involved mutation of the first lysine, lysine-247, to arginine. We realised that rather 
than use PCR-based mutagenesis, which carries a significant risk of introducing unwanted mutations, 
the same effect could be achieved using sub-cloning alone for which the risk of mutations is less. As 
can be seen from Figure 3.9, YB-1220-324 contains a KpnI site (GGTACC, indicated in blue) between the 
first and the second lysines. Hence sub-cloning the KpnI/XhoI fragment from YB-1220-324-RRRR into 
the KpnI/XhoI sites of wild type YB-1220-324 would replace lysines 2, 3 and 4 with arginines, producing 
a construct dubbed “KRRR”. This was successfully achieved, as shown in Figure 3.12. The sequences 
were verified by direct sequencing and were found to be 100 % in agreement with the expected 
sequence, including replacement of codon AAA, corresponding to lysine, with CGC, corresponding to 
arginine, in positions 2, 3 and 4 (Appendix). 
 
Figure 3.12: Sub-cloning of YB-1220-324-KRRR mutant into pGEX-HA-DWNN-GG. YB-1220-324-KRRR was constructed by sub-
cloning the KpnI/XhoI fragment from YB-1220-324–RRRR into wild type YB-1220-324. Lanes 2 and 3 contain the uncut wild type 
YB-1220-324 and YB-1220-324 -RRRR constructs respectively. Lanes 4 and 5 contain the same constructs digested with XhoI and 
KpnI releasing a 151 bp insert in each case. 
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3.4.4.          Expression and purification of wild type YB-1220-324 and the RRRR and RKKK mutants 
 
The pGEX-HA-YB-1220-324-6xHis construct was transformed into the E. coli BL21 expression host and 
used to over-express wild type GST-HA-YB-1220-324-6xHis. Taking advantage of the GST tag the fusion 
protein was purified using glutathione affinity chromatography, followed by nickel ion affinity, as 
shown in Figures 3.13(A). The fusion protein migrates at the expected molecular weight of 
approximately 40 kDa, corresponding to 27 kDa (GST) plus 12.5 kDa (YB-1220-324-6xHis). Unfortunately 
a number of lower molecular weight bands were present despite the use of two purification 
methods. Nevertheless the GST-tag was cleaved using 3C protease and separated from YB-1220-324 
using a second round of glutathione affinity chromatography.  
 
Figure 3.13: Purification of HA-YB-1220-324-6xHis fusion protein (A) YB-1220-324 was first purified using a glutathione agarose 
column, taking advantage of the N-terminal GST tag. Lanes 6-9 contain a 40 kDa band corresponding to the expected size 
of GST-HA-YB-1220-324-6xHis. (B) Following cleavage with GST-HRV 3C GST and HA-YB-1220-324 was separated on a glutathione 
agarose column. Lane 2 contains the cleaved sample before purification with 2 major bands 26 and 24 kDa in size 
corresponding to the size of GST and YB-1220-324. Lanes 4-8 contain the column wash fractions which contain both GST and 
YB-1220-324. Lanes 9 and 10 contain the elution fractions which contain GST. (C) YB-1220-324 was further purified using a 
HisTrap affinity column. Lanes 2-4 contain the flow through fractions which contain GST and GST-HRV 3C. Lane 6-10 
contains the elution fractions which contain YB-1220-324 and residual GST.  
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Figure 3.13(B) confirms that the fusion protein was efficiently cleaved by the 3C protease, producing 
two distinct bands, and confirms that the top band is GST, since it is eluted from the column by free 
glutathione (lanes 9 and 10). Surprisingly HA-YB-1220-324-6xHis,, which is the lower band, migrates at 
an effective molecular weight of approximately 24 kDa, which is almost twice the expected size of 
12.5 kDa.  Although some of the GST was retained by the column and eluted in lanes 9 and 10, the 
procedure did not result in effective separation of GST from HA-YB-1220-324-6xHis in lanes 3-6.  
Taking advantage of the C-terminal 6xHis-tag, nickel ion affinity chromatography was used to 
remove the remaining GST. Figure 3.13(C) shows that this method was more successful in separating 
the two proteins, with most of the GST remaining in the flow through and most of HA-YB-1220-324-
6xHis being eluted from the column following addition of 500 mM imidazole, with much reduced 
contamination by GST. Samples of YB-1220-324 -RRRR and YB-1220-324 -KRRR were expressed in the same 
way, with efficiencies similar to that of the wild type, as shown in Figures 3.14(A) and (B) 
respectively. 
     
 
Figure 3.14: Expression and purification of GST-HA-YB-1220-324 mutants -RRRR and -KRRR. (A) HA-YB-1220-324-RRRR was 
purified using a glutathione agarose column. Lanes 7-10 contain a 40 kDa band that corresponds to the expected size of 
GST-HA- YB-1220-324 -6xHis-RRRR. (B) Glutathione agarose purification of GST-HA-YB-1220-324 -6xHis-KRRR. Lanes 7-10 contain 
a 40 kDa band that corresponds to the expected size of GST-HA-YB-1220-324 -6xHis-KRRR.  
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3.4.5. The RING finger of RBBP6 and the YB-1220-324 fragment co-precipitate each other in GST pull-
down assays 
 
Interaction between full length YB-1 and RBBP6 in human cell lysate was shown in Section 3.5. In 
order to investigate whether the YB-1220-324 fragment of YB-1 interacts directly with the RING finger 
of RBBP6 in vitro, GST affinity pulldown assays were performed using GST-RBBP6-RING conjugated to 
glutathione agarose beads as “bait” and wild type HA-YB-1220-324-6xHis as “prey”. The expected 
molecular weight of HA-YB-1220-324-6xHis is 12.5 kDa. Following incubation and extensive washing the 
proteins retained by the beads were analysed by western blotting using the polyclonal anti-YB-1 
antibody described in Section 2.1. As shown in Figure 3.15, GST-RBBP6-RING was able to pull down 
HA-YB-1220-324-6xHis (lane 5), whereas neither GST alone (lane 3) nor the glutathione-conjugated 
beads alone were able (lanes 4). Although small amounts of HA-YB-1220-324-6xHis are evident in lanes 
3 and 4, there is significantly less than in lane 5, and is most likely due to insufficient washing of the 
beads.  
 
 
Figure 3.15: Immunodetection of wild type HA-YB-1 220-324-6xHis (KKKK) precipitated by GST-RBBP6-RING. GST-RBBP6-
RING is able to precipitate YB-1220-324-6xHis (lane 5), whereas GST and the glutathione-conjugated beads alone cannot 
(lanes 4 and 3 respectively).  Equal amounts of HA-YB-1220-324-6xHis  and equal amounts of glutathione agarose were added 
to lanes 3, 4 and 5. Ten times less YB-1220-324 was added to lane 2, which was not subjected to pull-down, compared to 
lanes 3-5. 
In lanes 3-5 HA-YB-1220-324-6xHis predominantly migrates at its expected molecular weight of 12.5 
kDa, whereas when loaded directly onto the gel it migrates at around 24 kDa (lane 2), which is 
consistent with its behaviour during purification (Fig 3.13, (C) and (D)). Smaller amounts can be seen 
at both molecular weights in all lanes. This anomalous behaviour of the C-terminus of YB-1 has been 
reported previously (Evdokimova et al., 1995) and may be the result of the highly charged nature of 
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the CTD of YB-1. Nevertheless lanes 3-4 suggest that the change in its behaviour may be the result of 
the presence of the glutathione agarose.  
Taking a more quantitative approach, lanes 3-5 contain 10 times the amount of prey as was loaded 
in lane 2 (which was loaded directly onto the gel without precipitation). After the final wash 
glutathione agarose pellets were re-suspended in 30 µl SDS sample buffer, of which 15 µl was loaded 
on a SDS PAGE gel for analysis. Hence if all of the prey in lane 5 were pulled down we would expect 
the signal in lane 5 to be 10/2 = 5 x more intense than that in lane 2. The differing banding patterns 
in lane 2 and lane 5 make comparisons difficult, but a rough estimate suggests that the signal in lane 
5 is of the order of 5 times that in lane. Hence we conclude that HA-YB-1220-324-6xHis does interact 
with the RING finger of RBBP6, and that the interaction is relatively strong. 
To further confirm the interaction the roles of the bait and prey were swopped around: GST-HA-YB-
1220-324-6xHis was used as bait and RBBP6-RING as prey. The results were analysed by western 
blotting using a polyclonal antibody targeting RBBP6-RING (Section 2.1), which detected a single 
band below 20 kDa, as can be seen in lane 3 of Figure 3.16, which was loaded directly onto the gel 
without pull-down. Equal amounts of RBBP6-RING were loaded in lanes 6 and 8 (nothing was loaded 
in lane 7). GST-HA-YB-1220-324-6xHis was able to pulldown RBBP6-RING (lane 8), whereas neither GST 
alone (lane 6) nor the glutathione-conjugated beads (lane 5) were able to, at least to the same 
extent.  
 
Figure 3.16: Immunodetection of RBBP6 RING precipitated by GST-HA-YB-1220-324-6xHis. Equal amounts of RBBP6 RING 
and glutathione agarose was added to lanes 5,6 and 8. GST-YB-1220-324 WT is able to precipitate RBBP6 RING 10 kDa Lane 8, 
whereas GST and the beads Lanes 6 and 5 respectively cannot. The faint band in lane 6 is much less intense compared to 
lane 8 and represents background. Lane 3 contains the RBBP6 RING as a control.  Equal amounts of RBBP6-RING and 
glutathione agarose beads were added to lanes 5-8 and pull down assays conducted as described previously. Five times 
less RBBP6-RING was added to lane 3 then pulldown lanes and no pull down was carried out, to serve as a molecular 
weight marker for RBBP6-RING. 
 
 
 
 
 
47 
 
 
Again taking more quantitative approach lanes 5-8 contain 5 times as much RBBP6-RING as lane 3. 
After the final wash glutathione agarose pellets were resuspended in 30 µl SDS sample buffer of 
which 10 µl was loaded on a SDS PAGE gel for analysis. Hence if all of the prey in lane 8 were pulled 
down we would expect the signal in lane 8 to be 5/3 = 1.7 x more intense than that in lane 3. In 
actual fact the signal in lane 8 is of the order of half as much as that in lane 3, which suggests that 
significantly less than 100 % of RBBP6-RING was precipitated. While this result disagrees with that 
from the reciprocal assay, it nevertheless provides independent confirmation that a significant 
interaction exists between the RING finger of RBBP6 and the YB-1220-324 fragment of YB-1. 
As has been mentioned above, a co-worker has shown, using samples prepared as part of this work, 
that wild type HA-YB-1220-324-6xHis is ubiquitinated by RBBP6 whereas the RRRR mutant is not, as 
expected, due to the absence of lysines. Since we have shown above that HA-YB-1220-324-6xHis 
interacts directly with RBBP6-RING, an alternative explanation for the lack of ubiquitination of HA-
YB-1220-324-6xHis-RRRR that needs to be ruled out is that HA-YB-1220-324-6xHis-RRRR does not interact 
directly with RBBP6-RING. In order to investigate this possibility a GST-pull down assay was used to 
investigate whether HA-YB-1220-324-RRRR could co-precipitate RBBP6-RING. Consistent with the 
previous result, wild type HA-YB-1220-324-6xHis (lane 5) precipitates RBBP6-RING significantly better 
than either GST alone (lane 4) or when no bait is present (lane 3). Surprisingly, lane 6 suggests that 
HA-YB-1220-324-6xHis-RRRR co-precipitates RBBP6-RING significantly better than wild type HA-YB-1220-
324-6xHis (lane 5 Nominally equal amounts of wild type and mutant HA-YB-1220-324-6xHis and equal 
amounts of RBBP6-RING were added to lanes 5 and 6, and although the amounts might not have 
been exactly equal, it is unlikely that any differences would account for the large differences 
between the bands in lanes 5 and 6. Ideally the western blot should have been stripped and re-
probed with antibodies against YB-1 in order to show that the amounts of wild type and mutant HA-
YB-1220-324-6xHis were in fact equal. Nevertheless we can conclude that HA-YB-1220-324-6His-RRRR 
interacts with RBBP6-RING at least as well as with wild type HA-YB-1220-324-6His and therefore the 
lack of ubiquitination of YB-1220-324-6His-RRRR by RBBP6 can only be due to the absence of lysine 
residues. It is therefore a suitable negative control for wild-type YB-1220-324 in ubiquitination assays as 
it still binds to RBBP6 but can’t be ubiquitinated. 
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Figure 3.17: Immunodetection of RBBP6-RING precipitated by GST-HA-YB-1220-324-6xHis-KKKK and -RRRR. GST-YB-1220-32-
KKKK and -RRRR are able to precipitate RBBP6-RING 10 kDa (lanes 5 and 6 respectively), whereas GST and the beads (lanes 
3 and 4 respectively) cannot. The feint band in lane 4 is much less intense compared to lanes 5 and 6 and represents 
background. Equal amounts of RBBP6-RING and glutathione agarose beads were added to lanes 3-6 and pull down assays 
conducted as described previously. RBBP6-RING was added to lane 2 but no pull down was carried out 
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3.5. UbcH1 interacts with the RING finger of RBBP6 in vitro 
3.5.1. Expression and purification of UbcH1 
 
A cDNA construct encoding UbcH1 was obtained from the Addgene repository (Plasmid No: 31436, 
deposited by Prof. Rachel Klevit, University of Washington, Seattle) and cloned into the pGEX-6P-2 
bacterial expression vector by Ms Lauren Jooste, a co-worker in the Pugh laboratory at UWC. The 
final construct was fully validated by direct DNA sequencing. GST-UbcH1 was expressed in E. coli 
BL21 and purified away from the endogenous E. coli proteins using a gravity flow glutathione 
agarose column, as described earlier in this thesis. Significant quantities of the 48.4 kDa fusion 
protein (GST 26 kDa; UbcH1 22.4 kDa) can be seen migrating at approximately 50 kDa in lanes 6-9 of 
Figure 3.18(A). 
Uncleaved GST-UbcH1 was used for the pull-down assay described below. For NMR analysis the GST 
tag was cleaved using 3C protease and separated from UbcH1 by a second round of glutathione 
affinity chromatography, with GST being retained by the column and UbcH1 collected in the flow 
through (see Figure 3.18(B)). This procedure was complicated by the similarity in size between GST 
(26 kDa, lane 7) and UbcH1 (22.4 kDa, lanes 2 and 3), requiring a number of rounds of purification to 
eliminate residual GST. During this process UbcH1 appears to have become partially proteolysed, 
yielding a fragment around 18 kDa in addition to the 22.4 kDa bands, as seen in Figure 3.18 (B). Final 
purification and exchange into NMR buffer was carried out using a Hiload Superdex 75 16/600 SEC 
column, as shown in Figure 3.18(C), by which time the lower, presumably proteolysed fragment, was 
predominant. Mass spectrometric analysis confirmed that the sample contained only fragments of 
between 19 and 20 kDa, as shown in Figure 3.18(D), compared with the expected mass of 22.4 kDa. 
Since the ubiquitin-associated domain (UBA) of UbcH1 comprises the last 40 residues of the protein 
(residues 160 – 200), with a molecular weight of around 4.5 kDa, and is attached to the E2 domain 
via a flexible linker, it is highly probable that the UbcH1 sample had been truncated near the 
beginning of the UBA. 
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Figure 3.18: Expression and purification of UbcH1. (A) UbcH1 was purified using a glutathione agarose column. Lanes 6-9 
contain ~50 kDa bands which correspond to the expected size of GST-UbcH1 (GST 26 kDa and UbcH1 22.4 kDa). The 
purified protein was then cleaved with recombinant 3C protease. (B) Following cleavage the protein was purified from GST 
using a glutathione agarose column. UbcH1 underwent partial proteolysis with two major bands ~22 kDa and ~18 kDa in 
lanes 2 and 3. (C) Concentrated UbcH1 was further purified using Size Exclusion Chromatography. Lane 1 contained a 
concentrated sample containing multiple bands with two major bands 22 kDa and 19 kDa corresponding to UbcH1 and 
UbcH1 degradation product respectively. (D) Mass spectrometry spectrum of pooled sample confirming the presence of 
fragments with masses around 19 and 20 kDa, compared to the expected mass of 22.5 kDa. This is likely to be the result of 
proteolytic removal of the UBA domain which makes up the last 40 residues of UbcH1. 
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3.5.2.  UbcH1 binds to the RING finger domain of RBBP6 in vitro 
 
A glutathione-affinity pull-down assay was carried out using GST-UbcH1 as bait and the RING finger 
of RBBP6 (RBBP6-RING) as prey, as shown in Figure 3.19. Equal quantities of glutathione-conjugated 
agarose and RBBP6-RING were added to each of lanes 4-6 and immunodetection of RBBP6-RING was 
carried out using a poly-clonal rabbit antibody raised against recombinant RING finger as described 
earlier in this thesis. 
GST-UbcH1 was was able to precipitate RBBP6-RING very effectively (lane 6), whereas isolated GST 
was not (lane 5) and nor was the glutathione-conjugated agarose alone (lane 4). Comparison with 
lane 3, which contains only, RBBP6-RING, to which no pull down was applied, confirms that what is 
precipitated in lane 6 is indeed RBBP6-RING, but significantly more concentrated than that in lane 3.  
The strength of the signal in lane 6 suggests that a large fraction of the prey has been precipitated. 
More quantitatively, 10 times the amount of RBBP6-RING was added to the precipitation assay (lane 
6) than what was added to lane 3, which was not subject to pull down. A ¼ of the final precipitate 
was loaded in lane 6. Hence if all of the prey were precipitated we would expect the signal in lane 6 
to be ¼ * 10 = 2.5 times as intense as that in lane 3. It looks significantly more intense than that, 
which throws some doubt on the result. Unfortunately neither an anti-UbcH1 nor an anti-GST 
antibody was available in the laboratory, so the interaction could not be repeated the other way 
around. Nevertheless we conclude that a definite interaction was observed between RBBP6-RING 
and UbcH1. 
 
Figure 3.19: Immunodetection of recombinant RBBP6 RING precipitated by GST-UbcH1. Equal amounts of bacterially-
expressed RBBP6-RING and glutathione-agarose beads were added to lanes 4-6. Bait proteins were added as indicated in 
the key. GST-UbcH1 was able to pull-down RBBP6-RING (lane 6), which is clearly the same protein as was added to lane 3, 
but which was not subjected to precipitation. When GST alone was used as bait (lane 5), or the bait was omitted altogether 
(lane 4), RBBP6-RING not was co-precipitated. 
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3.5.3. Chemical shift perturbation of 15N-labelled RBBP6-RING finger by un-labelled UbcH1 
 
The interaction between UbcH1 and the RING finger domain of RBBP6 was investigated further by 
NMR chemical shift perturbation assay. This assay investigates the chemical shift changes produced 
in the 15N-HSQC spectrum of a 15N-enriched protein when a second, un-labelled, protein is added. 
The un-labelled protein is not detected in the 15N-HSQC spectrum; only its effects on the spectrum of 
the labelled protein are detected. The assay has been shown to be a very sensitive measure of 
protein-protein interactions (Ko et al. 2010); where the 15N-HSQC of the labelled protein has been 
assigned, as it has in the case of RBBP6-RING, the assay allows for immediate identification of 
residues adjacent to the interaction interface. 
A 15N-labelled sample of RBBP6-RING was expressed and purified as described in the previous 
section. As is evident from Figure 3.18 UbcH1 expressed very well but was partially proteolysed 
during the purification steps. UbcH1 was concentrated into 400 µl without any major aggregation to 
a final concentration of 31.3 mg/ml, which for a 22.4 kDa protein corresponds to 1.4 mM. A 0.15 mM 
sample of 100 % 15N-enriched RBBP6-RING was produced as described in Section 3.4 and used to 
record a 15N-HSQC spectrum at 500 MHz for 8 hours. As seen in Figure 3.20(A) the spectrum shows 
good dispersion of resonances in both the 1H and 15N dimensions, which is indicative of a folded 
protein. The spectrum is also consistent with the assigned spectrum published by Kappo and co-
workers (Kappo et al. 2012), although it is a much weaker sample. 20 µl, 60 µl, 100 µl and 140 µl of 
unlabelled UbcH1, corresponding to labelled:unlabelled molecular ratios of 1:0.3, 1:0.9, 1:1.5 and 
1:2.2 respectively, were then added, and a 15N-HSQC spectrum recorded following each addition, 
each taking 8 hours to record. An overlay of the spectra, each in a different colour, is shown in Figure 
3.20(B).  
A number of chemical shift changes are visible, such as those indicated by squares and shown in 
Figure 3.20(B). However the directions and magnitudes of these shifts are consistent with 
concentration-induced effects produced by the increases in volume brought about by addition of 
UbcH1. RBBP6-RING is known to be a mixture of monomer and homo-dimer at these concentrations, 
with the NMR spectrum being a population-weighted average of the two conformations (Kappo et 
al. 2012). Even small reductions in concentration will shift the equilibrium towards the monomeric 
conformation, with corresponding effects on the spectrum. Comparison of panels (C) of Figure 3.20 
with Figure 5 of Kappo et al (2012) shows that the chemical shift perturbations in this study are 
consistent with the low-concentration end of the concentration range used by Kappo and co-
workers. This is as expected because the concentrations used in this study are in the range 150 µM – 
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120 µM (150 µM * dilution factor 600 µl/740 µl), whereas those used by Kappo and co-workers 
range from 1000 µM – 25 µM. 
 
 
Figure 3.20: 
15
N-HSQC spectra of the RBBP6 RING finger with and without unlabelled UbcH1. A) 
15
N-HSQC spectrum of 
the RING finger domain was acquired at 25 °C on a 500 MHz spectrometer. The spectrum shows good dispersion of 
resonances, in both the 
1
H and 
15
N dimensions, indicative of a folded protein. B) The overlay of the 
15
N-HSQC RING 
spectrum with no unlabelled UbcH1 (red) overlaid with the 
15
N-HSQC RING spectrum with 20 µl (blue), 60 µl (blue), 100 µl 
(green) and 140 µl (purple) unlabelled UbcH1. C) Zoomed in chemical shifts observed upon addition of unlabeled UbcH1 
which illustrates the shift from dimer to monomer.  
 
 
 
 
54 
 
The conclusion to be drawn from Figure 3.20 is that any chemical shift perturbations produced in the 
RBBP6-RING spectrum by UbcH1, following subtraction of the concentration effect, are likely to be 
small. Hence the data does not support anything more than a weak interaction between RBBP6-
RING and UbcH1 which contradicts the conclusion drawn from the pull down assay shown in Figure 
3.19. However, since the mass spectrum in Figure 3.18 suggests that the sample of UbcH1 used in 
the assay does not include the UBA domain one possible explanation for the lack of interaction is 
that the UBA is required for the interaction. The samples used in the pull-down shown in Figure 3.18 
did not undergo the drawn-out series of purification steps used for production of the NMR sample 
and therefore are less likely to have suffered proteolytic removal of the UBA domain.  
A second conclusion to be drawn from the above NMR study is that any chemical shift perturbation 
studies based on the 15N-HSQC spectrum of RBBP6-RING are likely to be complicated by the intrinsic 
concentration-dependence of the spectrum. One way of overcoming this problem would be to base 
the assay on the 15N-HSQC of UbcH1 rather than of RBBP6-RING. This will involve optimisation of 
expression of UbcH1 in minimal media for production of 15N-labelled samples of the protein. 
However the high levels of expression and the lack of difficulty in concentrating the sample to mM 
concentrations suggests that this approach has a good chance of succeeding.  
An alternative approach would be to base the investigation on the 15N-HSQC of a monomeric form of 
RBBP6-RING. We have previously reported that the N312D and K313E mutants of RBBP6-RING are 
monomeric and that their 15N-HSQC spectra are significantly less sensitive to changes in 
concentration than the spectrum of the wild type (Kappo et al 2012). The line-shapes of the spectra 
are also narrower than those of the wild type, as would be expected due to the smaller effective 
molecular weight of the protein, with the result that both resolution and sensitivity would be 
improved, boosting the chances of successfully carrying out the assay. Unpublished data from the 
Pugh laboratory shows that both the wild-type and mutants forms of the RBBP6-RING are able to 
auto-ubiquitinate themselves with UbcH1 playing the role of E2 which suggests that the monomeric 
form of UbcH1 still interacts with RBBP6-RING. Nevertheless it would be prudent to begin by 
showing that the mutant forms show significant interaction with UbcH1 using pull down assays, 
before going to the trouble of carrying out the NMR-based assay. 
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3.6. MDM2 interacts directly with the RING finger domain of RBBP6 in vitro 
 
Li and co-workers reported previously that RBBP6 interacts with MDM2 in vivo (Li et al., 2007). Our 
own results suggest that the R3 fragment of RBBP6, which consists of the first 335 amino acids of full 
length RBBP6 and contains the DWNN domain, the zinc knuckle and the RING finger domain, 
cooperates with MDM2 in vitro in ubiquitinating p53. Hence we would expect to observe a direct 
interaction between the R3 fragment of RBBP6 and MDM2 in in vitro immunoprecipitation studies. 
The R3 fragment had previously been shown in our laboratory to be suitable for expression in 
bacteria. Before trying to conduct a fully in vitro interaction with bacterially expressed MDM2, we 
decided to use endogenous MDM2 present in mammalian cells.  
3.6.1. Co-precipitation of endogenous MDM2 by the R3 fragment of RBBP6 
 
R3 was expressed in bacteria as a fusion with GST by a co-worker in the laboratory, Miss Portia 
Matodzi Maumela. HeLa cell lysate was supplied by Miss Andronica Ramaila, another co-worker in 
the laboratory. A glutathione-affinity pull down assay was carried out using GST-R3 as the bait and 
MDM2 as the prey, detecting MDM2 by western blot using antibody AB38618 (Abcam – Cambridge, 
MA, USA). This antibody recognises an epitope within residues 393-424 of MDM2 and has been 
shown to detect a band of 55 kDa, which corresponds to the expected size of MDM2, in mouse lens 
cells (Geatrell et al., 2009). Note that this is at variance with other data showing that MDM2 
migrates as a 98 kDa protein on SDS-PAGE (Jiang et al., 2013). Although not published data, a 
number of reviews on the manufacturer’s webpage for this antibody show detection of a 55 kDa 
band, which provide evidence that the protein detected by this antibody is in fact MDM2.  
As can be seen from Figure 3.21 GST-R3 was able to precipitate a 55 kDa protein from HeLa cell 
lysate (lane 5). A similar-sized protein was detected in lysate which had not been subject to 
precipitation (lane 2), which is as expected. A similar-sized protein was also detected when the pull 
down was carried out without any bait (lane 3) or with GST as bait (lane 4), but the intensities are 
much less than when GST-R3 was used as bait. This is likely to be due to insufficiently stringent 
conditions during the wash steps. Nevertheless Figure 3.21 represents clear evidence of direct 
interaction between the R3 fragment of RBBP6 and endogenous MDM2.  
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Figure 3.21: Immunodetection of endogenous MDM2 precipitated by GST-R3. Equal amounts of HeLa cell lysate and 
glutathione-agarose beads were added to lanes 3-5. Bait proteins were added as indicated in the key. GST-R3 was able to 
pull-down a protein of approximately 55 kDa (lane 5) which is also present in lysate not subjected to precipitation (lane 2). 
Smaller amounts of the same protein are present when no bait of GST is used as bait, but this is most likely to be due to 
insufficiently stringent washing of the beads. 
3.6.2. Co-precipitation of recombinant RBBP6-RING by recombinant MDM2 in vitro 
 
Encouraged by the interaction between recombinant R3 and endogenous MDM2 described above, 
we decided to investigate whether the interaction with MDM2 involves the RING finger of RBBP6. 
This time recombinatly-expressed, rather than endogenous, MDM2 was used as bait, fused to GST to 
facilitate pull down with glutathione agarose. Bacterially expressed RBBP6-RING was used as prey, 
detected using a rabbit polyclonal antibody raised against RBBP6-RING. Figure 3.22 shows that 
RBBP6-RING was precipitated when GST-MDM2 was used a bait (lane 5), but not when GST alone 
was used as bait (lane 4), nor when bait was left out altogether (lane 3). 
 
Figure 3.22: Co-precipitation of RBBP6-RING by GST-MDM2 in vitro. Equal amounts of bacterially-expressed RBBP6-RING 
and equal amounts of glutathione-agarose beads were added to lanes 3-5. Bait proteins were added as indicated in the 
key. GST-MDM2 was able to pull-down RBBP6-RING (lane 5) which is clearly the same protein as was added to lane 2, 
which was not subjected to precipitation. RBBP6-RING was not precipitated when GST alone was used a bait (lane 4) nor 
when bait was omitted altogether (lane 3). 
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The un-precipitated control in lane 2 contains 5 µl of the prey sample. 50 µl was RBBP6-RING was 
added to the precipitation (lane 5) 10x the amount added to lane 2 (which was not subjected to pull-
down) and ¼ of the final precipitate was loaded in lane 5. Hence if all of the prey were precipitated 
we would expect the signal in lane 5 to be ¼ * 10 = 2.5 times as intense as that in lane 2. It looks 
significantly less intense than that, which may suggest that the interaction between GST-MDM2 and 
RBBP6-RING is relatively weak.  
The above results, although preliminary, show a consistent interaction between RBBP6 and MDM2, 
using a variety of methods. Furthermore they suggest that the interaction can be localised to the 
RING finger domain of RBBP6. 
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Chapter 4 
 
Discussion and conclusions 
The primary aim of this study was to gain further insight into the role RBBP6 plays in the regulation 
of the cancer-associated proteins YB-1 and p53. In particular we aimed to confirm, in vitro, the 
presence of interactions and to localise them where possible to fragments suitable for future NMR-
based interaction assays. The study starts with a side project in which DWNN-GG, a fragment of the 
DWNN domain terminating immediately after the C-terminal di-glycine motif, was successfully 
cloned into pGEX-6P-2, including an HA tag inserted between the 3C protease site and the multiple 
cloning cassette, creating the construct pGEX-HA-DWNN-GG. The HA tag was inserted in such a 
manner that the DWNN-GG sequence could be excised and replaced with any other gene flanked by 
BamHI and XhoI sites, to yield a HA-tagged expression product. This property was used later in this 
thesis to generate the GST-HA-YB-1220-324-6xHis expression construct. The pGEX-HA-DWNN-GG 
construct was designed to be used by co-workers investigating whether the DWNN domain becomes 
covalently attached to other proteins when added to mammalian cell lysate.  
The interaction between endogenous RBBP6 and YB-1 was confirmed in human lysate by 
precipitating RBBP6 and detecting YB-1. The interaction appeared to be a significantly strong based 
on a rough quantitative analysis. This is in good agreement with the findings of Chibi and co-workers 
(Chibi et al., 2008) as well as our recent unpublished data that RBBP6 is able to poly-ubiquitinate YB-
1 in vitro. In order to localise the interaction further on YB-1, the C-terminal fragment described by 
Sorokin and co-workers (Sorokin et al., 2005), denoted YB-1220-324, was successfully cloned and 
solubly over-expressed in bacteria. The RING finger from RBBP6 was similarly over-expressed and 
purified. 
The expected interaction between YB-1220-324 and RBBP6-RING was confirmed using GST pull-down 
assays, first with GST-RBBP6-RING as bait and YB-1220-324 as prey, and then the other way around, 
significantly increasing the significance of the result. Attempts to over-express YB-1220-324 on a scale 
suitable for NMR studies were unsuccessful due to protein stability issues. Performing the 
interaction assay the other way around – recording the 15N-HSQC of 15N-labelled YB-1220-324 and 
adding unlabelled RBBP6-RING - may be a better strategy, since it would significantly reduce the 
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amount of YB-1220-324  required, whereas RBBP6-RING expresses very efficiently and is amenable to 
being highly concentrated. 
Since it contains 4 lysines compared to the 16 of YB-1, YB-1220-324 should be an ideal substrate for 
identification of the lysine or lysines serving as attachment points for poly-ubiquitination. A mutant 
was first synthesised in which all four lysines were mutated to arginines, yielding a protein dubbed 
YB-1220-324-RRRR. We then took advantage of a KpnI restriction enzyme site in YB-1220-324 to sub-clone 
the last three arginines from YB-1220-324-RRRR into wild type YB-1220-324, yielding the YB-1220-324-KRRR 
mutant. Due to time constraints the other 3 mutants could not be generated but will be the focus of 
future projects. Wild-type YB-1220-324 and the RRRR mutant were successfully expressed in bacteria 
and donated to a co-worker for use in fully in vitro ubiquitination assays. The results indicate that 
the R3 fragment of RBBP6 is able to poly-ubiquitinate YB-1220-324, which suggests that YB-1220-324 may 
serve as a useful substrate for investigating ubiquitination of YB-1 by R3, and possibly for 
determination of the structure of the R3/YB-1 complex.  As expected YB-1220-324-RRRR could not be 
ubiquitinated by R3, although it still  interacted with R3, and will therefore serve as a useful negative 
control in future ubiquitination studies. Time constraints did not permit investigation of the 
ubiquitination of the KRRR mutant. 
The demonstration of an interaction between YB-1220-324 and its ubiquitination by RBBP6 provides in 
vitro confirmation of the report by Chibi and co-workers that RBBP6 suppresses YB-1 in vivo by 
promoting its ubiquitination and degradation in the 26S proteasome. Furthermore it provides a 
robust in vitro platform for future investigations of the regulation of this important oncogene. The 
aims of such investigations will include the design mutants of YB-1 which cannot be ubiquitinated by 
RBBP6, as well as the design of small molecules able to disrupt the interaction of YB-1 and RBBP6, 
both for use in functional studies. While it is true that the above strategies will increase the 
oncogenic potential of YB-1 rather than decrease it, they will nevertheless increase our 
understanding of the importance of the both RBBP6 and YB-1 in tumourigenesis. The regulation of 
tumourigenesis is the result of a balance of many pro- and anti-tumourigenic factors, and it is only 
by fully understanding both kinds of factors that we can hope to intervene effectively. 
The in vitro interaction between RBBP6 and the ubiquitin-conjugating enzyme UbcH1 provides 
support to our data showing RBBP6 is able to poly-ubiquitinate YB-1 with the help of UbcH1 as 
ubiquitin-conjugating enzyme.  The successful bacterial over-expression of NMR-quality samples of 
UbcH1 lays the foundation for future structural investigations of this interaction, including 
elucidation of the structure of the RBBP6-RING/ UbcH1 complex using NMR and identification of 
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amino acids whose mutation may modulate the activity of the pathway and would therefore be 
useful for future functional studies. The attempts reported here to validate and investigate the 
interaction using NMR were unsuccessful, most probably due to proteolytic cleavage of the UBA 
domain found at the C-terminus of UbcH1. From this it can be concluded that more care must be 
taken in purification of UbcH1. As in the case of YB-1220-324 above, performing the interaction assay 
the other way around – recording the 15N-HSQC of 15N-labelled UbcH1 and adding unlabelled RBBP6-
RING - may be a better strategy, since it would significantly reduce the amount of UbcH1 required. 
The localisation of the previously-reported interaction between RBBP6 and MDM2 to the RING 
finger domain of RBBP6, both in lysate and in fully in vitro assays, lends support to our model in 
which RBBP6 and MDM2 interact though their respective RING finger domains. The successful use of 
bacterially-expressed MDM2 lays the groundwork for future in vitro assays aimed at further 
localising the interaction on MDM2. 
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Appendix 
 
 
 
Query  1    ATGTACCCATACGATGTTCCAGATTACGCTGCGGGATCCATGTCCTGTGTGCATTATAAA  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTACCCATACGATGTTCCAGATTACGCTGCGGGATCCATGTCCTGTGTGCATTATAAA  60 
 
Query  61   TTTTCCTCTAAACTCAACTATGATACCGTCACCTTTGATGGGCTCCACATCTCCCTCTGC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TTTTCCTCTAAACTCAACTATGATACCGTCACCTTTGATGGGCTCCACATCTCCCTCTGC  120 
 
Query  121  GACTTAAAGAAGCAGATTATGGGGAGAGAGAAGCTGAAAGCTGCCGACTGCGACCTGCAG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GACTTAAAGAAGCAGATTATGGGGAGAGAGAAGCTGAAAGCTGCCGACTGCGACCTGCAG  180 
 
Query  181  ATCACCAATGCGCAGACGAAAGAAGAATATACTGATGATAATGCTCTGATTCCTAAGAAT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  ATCACCAATGCGCAGACGAAAGAAGAATATACTGATGATAATGCTCTGATTCCTAAGAAT  240 
 
Query  241  TCTTCTGTAATTGTTAGAAGAATTCCTATTGGAGGT  276 
            |||||||||||||||||||||||||||||||||||| 
Sbjct  241  TCTTCTGTAATTGTTAGAAGAATTCCTATTGGAGGT  276 
 
Figure A1: Alignment of the experimental sequence read of HA-DWNN-GG (Sbjct) with the expected sequence (Query): 
HA-tag indicated in green, BamHI site in red and di-glycine in yellow. Showed that the sequence was 100 % correct. 
Sequencing was carried out Inqaba biotech.  
 
 
 
Query  1    GGATCCGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATG  60 
 
Query  61   TATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG  120 
 
Query  121  GACGGCAATGAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GACGGCAATGAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCT  180 
 
Query  181  CAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCA  240 
 
Query  241  CAAGATGGCAAAGAGACAAAAGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  CAAGATGGCAAAGAGACAAAAGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAG  300 
 
Query  301  GCTGAGCAGGGCGGGGCTGAGCATCATCATCATCATCATTAACTCGAG  348 
            |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  GCTGAGCAGGGCGGGGCTGAGCATCATCATCATCATCATTAACTCGAG  348 
 
Figure A2: Alignment of experimental sequence of wild type YB-1220-324 (Sbjct) against the expected sequence 
(Query):The sequence was 100 % identical to the expected sequence performed at Inqaba Biotech facility, with four lysines 
(codon AAA), indicated in yellow, the flanking BamHI and XhoI sites indicated in turquoise and red respectively.  
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Query  1    GGATCCGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATG  60 
 
Query  61   TATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG  120 
 
Query  121  GACGGCAATGAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCT  180 
            ||||||||||||||||||   ||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GACGGCAATGAAGAAGATCGCGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCT  180 
 
Query  181  CAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCA  240 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||   ||| 
Sbjct  181  CAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTCGCCCA  240 
 
Query  241  CAAGATGGCAAAGAGACAAAAGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAG  300 
            |||||||||   ||||||   ||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  CAAGATGGCCGCGAGACACGCGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAG  300 
 
Query  301  GCTGAGCAGGGCGGGGCTGAGCATCATCATCATCATCATTAACTCGAG  348 
            |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  GCTGAGCAGGGCGGGGCTGAGCATCATCATCATCATCATTAACTCGAG  348 
 
Figure A3: Alignment of the experimental sequence of the YB-1220-324-RRRR mutant (Sbjct) against the expected 
sequence of the wild type (Query): The sequence was 100 % in agreement, with the exception of the four lysines (codon 
AAA), indicated in yellow, which have been replaced by arginines (codon CGC).  The KpnI restriction site used for 
generation of the KRRR mutant is indicated in purple.  
 
 
Query  1    GGATCCGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCGGTGCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATG  60 
 
Query  61   TATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TATCGGGGATATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAG  120 
 
Query  121  GACGGCAATGAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GACGGCAATGAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCT  180 
 
Query  181  CAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCA  240 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||   ||| 
Sbjct  181  CAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTCGCCCA  240 
 
Query  241  CAAGATGGCAAAGAGACAAAAGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAG  300 
            |||||||||   ||||||   ||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  CAAGATGGCCGCGAGACACGCGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAG  300 
 
Query  301  GCTGAGCAGGGCGGGGCTGAGCATCATCATCATCATCATTAACTCGAG  348 
            |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  GCTGAGCAGGGCGGGGCTGAGCATCATCATCATCATCATTAACTCGAG  348 
 
Figure A4: Alignment of the experimental sequence of the YB-1220-324-KRRR mutant (Sbjct) against the expected sequence 
of the wild type (Query): The sequences are 100 % in agreement, with the exception of the last three lysines, indicated in 
yellow. The KpnI restriction site is indicated in purple. 
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B1. List of chemicals, kits and suppliers 
Table B1: List of chemicals, kits and suppliers 
Chemical Supplier 
40% 37.5:1 acrylamide: bis-acrylamide  Sigma  
Agarose  Promega  
Ammonium persulphate  Merck  
Ampicillin  Roche  
Boric acid  Merck  
Bovine serum albumin  Roche  
Calcium chloride  Merck  
ClarityTM ECL Western Blotting Substrate Bio-rad 
Coomassie Blue R-250  Sigma  
Ethanol  Merck  
Ethylene diamine tetra acetic acid (EDTA)  Merck  
GeneJET Gel Extraction Kit Thermo Fisher Scientific 
GeneJET PCR Clean-up Kit  Thermo Fisher Scientific 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific  
Glacial acetic acid  Merck  
Glutathione agarose  Sigma  
Glycerol  Merck  
Glycine  Merck  
Hydrochloric acid  Merck  
Imidazole  Sigma  
Isopropanol  Merck  
Luria Broth  Merck  
N, N, N’, N’-Tetra methylethylene-diamine 
(TEMED)  
Sigma  
Nickel sepharose  Amersham Biosciences  
Nutrient agar  Merck  
Potassium acetate  Merck  
Potassium chloride  Merck  
Protease inhibitor cocktail  Roche  
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Restriction enzymes  Fermentas  
Sodium chloride  Merck  
Sodium dodecyl sulphate  Promega  
Tris Merck 
Tryptone  Merck  
Tween-20  Merck  
Yeast extract  Merck  
B2 List of general stock solutions and buffers 
Table B2: List of general stock solutions and buffers 
 
Buffer 
Composition/Preparation 
10 x PBS  1.37 M NaCl, 26.96 mM KCl, 88.75 mM 
N2HPO4.2H2O, 15 mM KH2PO4 at pH 7.4  
10x SDS  
electrophoresis  
buffer  
50 mM Tris, 0.2% SDS and 500 mM glycine, pH 
8.3  
10x TBE  0.9 M Tris (pH 8.3), 0.89 M boric acid and 25 mM 
EDTA. This stock was stored at room 
temperature and diluted ten-fold for running 
agarose gels  
2X SDS sample buffer  4 % SDS, 0.125 M Tris pH 6.8, 15 % glycerol and 1 
mg/ml bromophenol blue. This buffer was stored 
at room temperature. 10 % β- mercaptoethanol 
was added to the buffer immediately prior use.  
3C protease  
buffer  
50 mM Tris, pH 8.0, 200 mM NaCl, 20 mM β-
mercaptoethanol  
Ammonium persulphate  A 10 % stock solution was prepared in deionised 
water. The solution was stored at 4 °C. 
Ampicillin  A 100 mg/ml solution was made in deionised 
water, filter sterilised and stored at -20 °C.  
Coomassie staining solution  40 % ethanol, 10 % acetic acid, 0.1 % Coomassie 
Blue R-250  
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Destaining  
solution  
40 % ethanol, 10 % acetic acid.  
IPTG  1 M stock solution was prepared in deionised 
water, filter sterilised and stored at -20 °C  
Luria broth  1 % tryptone, 0.5 % yeast extract, 0.5 % NaCl and 
0.2 % glucose  
Minimal media 12.8 g/l Na2HPO4-7H2O, 3 g/l KH2PO4, 1 g/l 
NH4Cl and 0.5 g/l NaCl. The pH of this media was 
adjusted to 7.0 with NaOH and the solution was 
autoclaved. Immediately prior to use, the 
solution was supplemented with 2 ml of 
autoclaved 1 M MgSO4, 100 µl of autoclaved 1 
M CaCl2 and 10 ml of filter-sterilized 20 % 
Glucose. The solution was stored at room 
temperature. For labeled minimal media 1g/liter 
15N- labeled NH4Cl was added to the media. 
NMR buffer 100 mM Sodium phosphate buffer pH 6.0, 150 
mM NaCl, 5 mM DTT and 0.02 % sodium azide. 
PBS-T 1 X PBS and 0.1 % Tween 
Protein elution buffer 20 mM Glutathione, 50 mM Tris-HCl pH 8.0 and 
150 mM NaCl or 500 mM Imidazole, 50 mM Tris-
HCl pH 8.0 and 150 mM NaCl 
 
Protein extraction buffer  50 mM Tris, pH 8, 150 mM NaCl, 100 g/ml 
lysozyme, 10 mM-mercaptoethanol, 0.5 % Triton 
X-100, 20 μg/ml ZnSO4.  
Protein wash buffer 50 mM Tris, pH 8.0, 150 mM NaCl and 10 mM β- 
mercaptoethanol. 
Separating buffer 1.5 M Tris-HCl, adjusted to pH 8.8 with HCl. The 
buffer was stored at 4 °C. 
Stacking buffer 0.5 M Tris-HCl, adjusted to pH 6.8 with HCl. The 
buffer was stored at 4 °C. 
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